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 3 
Summary  
 
Inflammation-induced lung fibrosis represents a common final pathway of 
various pulmonary disorders, such as the adult respiratory distress syndrome, or 
interstitial lung diseases, such as idiopathic pulmonary fibrosis. Endogenous 
stem/progenitor cells might represent a novel cell-based therapeutic option combining 
tissue repair and anti-inflammatory effects.  
Here, we describe the identification of a novel population of prominin-
1/CD133
+
 progenitor cells from adult mouse lungs. Following digestion and culture 
of distal airways, we were able to expand high numbers of prominin-1
+
 progenitor 
cells. Prominin-1
+
 progenitors co-expressed stem and hematopietic cell markers, and 
were of bone marrow origin as suggested by the analysis of CD45.2 chimeric mice 
reconstituted with CD45.1 or GFP donor bone marrow. Immunohistochemistry 
revealed that bone marrow-derived prominin-1
+
 cells resided in the alveolar 
epithelium. Prominin-1
+
 progenitors showed multilineage differentiation capacities in 
vitro. Depending on culture conditions, they differentiated into alveolar type II 
surfactant protein-C positive epithelial cells, phagocyting macrophages, or fibroblast-
like cells. After intratracheal administration into mice, prominin-1
+
 progenitor cells 
engrafted in the alveolar epithelium and differentiated into type II pneumocytes. In 
order to evaluate the regenerative and anti-inflammatory capacity of prominin-1
+
 
progenitors, we used a mouse model of bleomycin (BLM)-induced lung injury. In this 
injury model, single intratracheal instillations of BLM into C57Bl/6 mice result in 
recruitment of inflammatory cells, infiltration of fibroblasts, and excessive collagen 
deposition and pulmonary fibrosis. In contrast to sham-treated control mice, following 
intratracheal transplantation of prominin-1
+
 cells completely protected the animals 
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from fibrosis development. The extent of pulmonary inflammation and fibrosis was 
assessed by histology, immunohistochemistry, bronchoalveolar lavage fluid 
differentials, and real-time RT-PCR. Prominin-1
+
 cells suppressed pro-inflammatory 
and pro-fibrotic gene expression and prevented the recruitment of inflammatory cells 
and fibrocytes. Mechanistically, the protective effect depended on the up-regulation 
of inducible nitric oxide synthase (iNOS) in prominin-1
+
 progenitor cells and nitric 
oxide mediated suppression of alveolar macrophage proliferations. Accordingly, 
prominin-1
+
 cells expanded from iNOS
-/-
, but not iNOS
+/+
 mice, failed to protect from 
BLM-induced lung injury. 
In conclusion, the combined immunomodulatory and regenerative capacity of 
bone marrow-derived prominin-1
+
 pulmonary progenitors makes them a promising 
option for novel cell-based treatment strategies against pulmonary fibrosis.  
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Introduction 
 
Idiopathic Pulmonary Fibrosis 
Tissue fibrosis represents the common final pathway for a large variety of 
pulmonary diseases such as adult respiratory distress syndrome, cystic fibrosis, 
interstitial pneumonia, sarcoidosis or idiopathic pulmonary fibrosis. These disorders 
result in distortion of pulmonary
 
architecture, which compromises pulmonary 
function. At the present, many end stage lung diseases are treatable with 
transplantation only. Due to its significant mortality and morbidity, this approach 
however remains palliative and the number of donor organs available is far 
outstripped by demand. 
Idiopathic Pulmonary Fibrosis (IPF) is the most common form of interstitial 
lung diseases of unknown origin. It is associated with an extremely poor prognosis. 
Life expectancy after diagnosis varies, but is on average less than 5 years (1, 2). A 
recent study has estimated its prevalence ranges from 14 to 42.7 cases and incidence 
ranges from 6.8 to 16.3 cases per 100,000 persons (3). Although during the past 
decades significant advances have been made in the understanding of the 
pathogenesis of IPF, the exact mechanisms underlying the development of IPF still 
remain unknown (4).  
More importantly, concepts of pathogenesis have shifted within the past years. 
Previously, the long held belief was that chronic inflammation plays an essential role 
in the pathogenesis of IPF (4-16). In this paradigm IPF is characterized by some 
degree of lung inflammation and abnormal tissue repair, resulting in the replacement 
of normal functional tissue with abnormal accumulation of fibroblasts and 
myofibroblasts and deposition of collagen and other extracellular matrix (ECM) in the 
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interstitial and alveolar spaces (6-16). This process is known to involve an intricate 
cytokine network that activates and mediates interactions between multiple cell types 
resulting in the elevation of collagen gene expression and abnormal collagen 
deposition in the lung (4-16) (Fig. 1). 
Another hypothesis is founded on the fact that IPF results from epithelial cell 
injury and abnormal wound repair in the absence of preceding inflammation (4, 17). 
A more recent concept is based on the modification of these two hypotheses and 
postulates that inflammation is subsequent to injury and IPF occurs as a result of the 
body’s immune response to lung injury (4). Thus, the pathogenesis of IPF may be 
much more complex than was previously thought, and IPF represents more likely a 
syndrome rather than a specific disease. The pathologic hallmarks of IPF are 
fibroblastic foci, representing areas rich in mesenchymal cells and ECM. These foci, 
consisting of fibroblast-like cells and myofibroblasts, are considered to be a key 
element in the diagnosis of IPF (11). Understanding the origin of these cells and the 
mechanism of their recruitment to the lungs should shed further insight into the basis 
for the development of progressive fibrosis, rather than successful healing and 
regeneration (11). Previous studies have suggested that fibroblasts and myofibroblasts 
in injured and fibrotic lung arise from fibroblast precursors residing in the adventitia 
of perivascular and peribronchial tissue. Recent evidence, however, rather supports 
the view that bone marrow-derived progenitor cells and circulating fibrocytes, which 
are known as progenitors for fibroblasts, may be recruited after lung injury and 
contribute to pathological tissue remodeling and fibrosis (11, 18-29).  
 
 
 
 9 
 
 
Figure 1. Pathogenesis of idiopathic pulmonary fibrosis: unknown stimuli promote injury activating 
multiple pro-inflammatory, reparative pathways. These cascades can result in an imbalance of pro- and 
antifibrotic mediators. In turn, these mediators activate multiple cell types, causing changes in cellular 
functioning and cell-to–cell interactions that ultimately result in progressive fibrosis. Th: T-helper cell; 
CTGF: connective tissue growth factor; TGF-ß1: transforming growth factor-ß; PDGF: platelet-derived 
growth factor; FXa: factor Xa; PG: prostaglandin; IFN-!: interferon-gamma; EMT: epithelial–
mesenchymal transition. (Adapted from Maher et al., Eur Respir J, 2007). 
 
 
The development of idiopathic pulmonary fibrosis, as well as initiation of 
other interstitial lung diseases, might represent a well-orchestrated process between 
different cells, characterized by elevated levels of inflammatory cytokines-producing 
cells that may direct the recruitment of cells to the lung and enhance cytokine 
production (30-34). Various cells, such as eosinophils, alveolar macrophages, T cells, 
neutrophils, and natural killer cells, are believed to be implicated in the pathogenesis 
of IPF, with alveolar macrophages contributing to the disease via cytokine release 
(35). Nevertheless, while the role of T cells in the development of fibrosis in response 
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remains controversial (36-39), the development of fibrotic lesions is dependent on the 
release of chemokines, most notably CCL2 or CCL12 from the injured lung, and the 
recruitment of inflammatory cells such as monocytes, lymphocytes, and then 
fibrocytes (14, 40-44). The profibrotic cytokine transforming growth factor (TGF)-#1 
is also critically involved in the development of pulmonary fibrosis (45, 46). 
Disordered coagulation cascades (47-49) and eicosanoid imbalances, which favor the 
overproduction of profibrotic leukotrienes and the underproduction of antifibrotic 
prostaglandins, are also noted (50). 
 
 
Bleomycin injury as a mouse model for idiopathic pulmonary fibrosis 
The bleomycin model of pulmonary fibrosis is the best-characterized mouse 
model in use today. Bleomycin was originally isolated from Streptomyces verticillatus 
(51) (Fig.2). It was subsequently found to be a potent anti-cancer drug, effective 
against squamous cell carcinomas and skin tumors (52); however, its usefulness as an 
anti-neoplastic agent was limited by dose-dependent pulmonary toxicity resulting in 
fibrosis (53). 
 
 
Figure 2. Chemical structure of bleomycin. 
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BLM has been shown to induce lung injury and fibrosis in a wide variety of 
laboratory animals including mice, rats, hamsters, rabbits, guinea pigs, dogs, and 
primates over a range of doses induced via intraperitoneal, intravenous, subcutaneous, 
or intratracheal delivery (53). One advantage of intravenous and intraperitoneal 
administration is that it more closely mimics the way humans are exposed to the drug 
regimen (54). Following intravenous administration of the drug, the first lesions affect 
the pulmonary endothelium. It is believed that initial damage of the pulmonary 
endothelium allows drug access to the lung interstitium where epithelial damage 
occurs subsequently (55). The pathological response to this injury has been well 
characterized (53) and includes leakage of fluid and plasma proteins into the alveolar 
space, alveolar consolidation, and formation of hyaline membranes. Later on, there is 
focal necrosis of type I epithelial cells and induction of type II epithelial cells 
metaplasia. Inflammatory infiltrates accumulate, and fibrosis develops in subpleural 
regions. A disadvantage of this model system, however, is that fibrosis does not 
develop in all animals, and the time frame for the development of fibrosis is relatively 
long (55). 
The delivery of BLM via the intratracheal route has the advantage that a single 
administration of the drug produces lung injury and subsequently fibrosis in rodents 
(56-58) In addition, injury is restricted to pulmonary tissue. Intratracheal delivery of 
BLM results in direct damage of alveolar epithelial cells. This event is followed by 
the development of neutrophilic and lymphocytic pan-alveolitis within the first week 
(59). Subsequently, alveolar inflammation resolves, fibroblasts proliferate and 
synthesize extracellular matrix (60) The development of fibrosis in can be seen 
biochemically and histologically by day 14, with maximal responses around days 21–
28 (59-62). Beyond 28 days, however, the response to BLM is more variable. Original 
 12 
reports suggest that BLM delivered intratracheally may induce fibrosis that progresses 
or persists for up to 60–90 days (58, 63, 64). In contrast, others report a self-limiting 
response resolving after 30-40 days (62, 65, 66). In humans, pulmonary interstitial 
fibrosis is largely – but not always - an irreversible process. From this point of view, 
the BLM model might also offer the opportunity to study the plasticity of the fibrotic 
response in general. 
In mice, the fibrotic response to BLM is strain-dependent. C57Bl/6 mice are 
much more susceptible to BLM-induced fibrosis than BALB/c mice (60, 67). This 
likely reflects strain-dependent differences in the expression of the inactivating 
enzyme, bleomycin hydrolase (68). Additionally, the fact that lungs are particularly 
sensitive to bleomycin toxicity is a reflection of the low levels of this enzyme in lung 
tissue compared with other body tissues (69). 
 
 
Current treatments for idiopathic pulmonary fibrosis 
In humans, IPF is a progressive and irreversible illness. So far, there are no 
drugs available with the capacity to modify the progressive natural disease course. 
Current treatments are based on the assumption that IPF is a chronic, unresolved 
inflammatory disease. Despite extensive research efforts over the past decades, no 
therapy has been shown to either reverse or even halt the progression of this disorder 
(5). The mainstay of therapy has been the use of corticosteroids with or without 
immunosuppressive drugs (70). However, it is now clear that therapies with anti-
inflammatory drugs are associated with severe side effects and minimal objective 
benefit (70). Recent progress in understanding the mechanisms underlying the 
pathogenesis of fibrosis leads us to expect that inhibitors of pro-fibrogenic cytokines 
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and growth factors may be useful as novel therapeutic agents in controlling 
undesirable fibrosis. Therefore, potential therapeutic strategies could be developed for 
use at any of the steps that result in IPF. The major therapeutic agents in lung fibrosis 
include anti-inflammatory drugs, anti-fibrotic and anti-cytokine agents, receptor 
antagonists, signal transduction pathways inhibitors, anti-apoptosis agents, and 
angiogenic and MMPs inhibitors (Fig. 3). 
 
 
 
 
Figure 3. Major targets for therapeutic intervention in pulmonary fibrosis. Current treatment options 
include agents that interfere with the action of inflammatory mediators, agents that prevent epithelial 
cell damage, agents that prevent fibroblast proliferation and collagen synthesis, agents that down-
regulate myofibroblast differentiation, agents that inhibit angiogenesis or stimulate angiostatic CXC 
chemokines, and agents that intervene with one or more key events in the pathogenesis or signal 
transduction pathways of IPF. Unfortunately, they cannot stop the condition from worsening, nor can 
they reverse the damage that has already occurred. Therefore, treatments for IPF are focused on 
minimizing further damage, along with relieving symptoms and improving a person's quality of life. 
Cell-based therapy may provide a new therapeutic option, contributing to regeneration of pulmonary 
epithelium. (Adapted from Gharaee-Kermani et al., Pharmaceutical Research, 2007). 
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Lung transplantation remains the only option for end-stage IPF (71). This 
procedure can prolong life and may improve the quality of the patient’s life. However, 
many patients die because of shortage of donated organs, obliterative bronchiolitis, 
infections, and other complications, and the high cost associated with organ 
transplant. Thus, given the paucity of current therapeutic options, the research has 
been focusing efforts towards development of novel restorative approach, such as 
cellular therapies. In the field of cell-based therapy, significant advances have been 
reached in the biology of adult stem or progenitor cells in the last years. Stem cells 
may therefore offer a new hope for the patients with lung disorders such as IPF, 
emphysema, and other fibrotic lung diseases. 
 
 
Stem cell-based treatment as a novel therapeutic option 
Stem cells are the self-renewing cells with the capacity to differentiate into 
specialized, or differentiated, cell types of a given tissue during a particular stage of 
life (72-79). Progenitor cells, in contrast, do not have self-renewal capability. Another 
defining characteristic of these cells is their niche (29). A niche is a subset of cells and 
extracellular components that can accommodate one or more stem cells indefinitely 
and control their self-renewal and progeny production in vivo. The stem cells 
undifferentiated character and capacity for unlimited self-renewal are a result of their 
interaction with the supportive cells and a unique microenvironment in their niche 
(26). 
Stem cells may be classified into two categories based on their origin: 
embryonic stem cells (ESC), and adult stem cells. ESC are pluripotent cells and are 
derived from the inner cell mass of the blastocyst stage of embryos (80). They are 
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able to form any cell type and tissue in the animal body (Fig. 4A) and therefore have 
great therapeutic capacity to regenerate any damaged tissue (81). The therapeutic 
capacity of these cells that proliferate freely in culture has been shown in several 
animal models of diseases, such as Parkinson’s disease (82, 83). Additionally, ESC 
can be generated in practically unlimited number. Although ESC have been suggested 
for use in tissue regeneration of pulmonary epithelium (84-87), their use is currently 
mired in substantial ethical controversy (88); moreover, they have to face a greater 
risk of teratoma formation and immune rejection (89). Use of autologous cells can be 
applicable, if new technology of reprogramming fibroblasts into ES-like cells 
becomes safe, reproducible and standardized for human cells (90). So far, all these 
barriers prevented experimental use of ESC in clinical trials. 
 
 
 
 
Figure 4. Stem cells for cellular therapy. (A) Embryonic stem cells are considered totipotent and 
therefore capable of giving rise to any cell type of an organism. (B) In contrast, bone marrow-derived 
cells can give rise to blood cells (HSCs), bone and adipose tissues (MSCs). Despite recent findings, the 
true contribution of bone marrow cells to other cell types is yet to be determined. (C) Adult 
stem/progenitor cells are believed to give rise mostly to cell type of their tissue origin. 
 
 
Among the adult stem cells, the most characterized and possible candidates for 
cell-based therapies are bone marrow-derived stem cells (Fig. 4B). Bone marrow is 
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the source of several distinct stem cell populations: a primary category is 
hematopoietic stem cells (HSCs), which are traditionally thought to give rise solely to 
cells of the hematopoietic series, such as leukocytes and erythrocytes, therefore 
maintaining or restoring mature circulating blood cells. The bone marrow also 
contains marrow stromal or mesenchymal stem cells (MSCs), which are populations 
that give rise to a variety of connective tissues localized in different germ layers. 
Moreover, a growing body of evidence indicates that MSCs also possess 
immunomodulatory properties (91), both in vitro (92) and in vivo (93, 94). Several 
studies have illustrated that bone marrow-derived stem cells possess a broader 
plasticity and differentiation potential, can circulate in peripheral blood and migrate to 
distant tissues/organs, and thereby contribute to promote tissue repair at injured sites 
(95-102). The true potential for the adult, bone marrow-derived stem cell populations 
in lung tissue regeneration remains to be determined. There remains some uncertainty 
as well as to whether they play a harmful role in IPF, such as by promoting 
fibrogenesis, or a beneficial reparative and/or regenerative role. 
Regarding tissue-specific not bone marrow-derived adult stem cells, the key to 
their identification resides in the ability to isolate them and show that they are capable 
of self-renewal and differentiation. Due to the intimate association between epithelial 
cells and their surrounding stroma, it was exceedingly difficult to identify solid tissue 
stem cells until recently (72, 103-105). Intense research on stem cells during the last 
decades has provided important information on developmental, morphological, and 
physiological processes that govern tissue and organ formation, maintenance, 
regeneration, and repair after injuries (95, 99, 106-110). In fact, in addition to stem 
cells from embryos, fetal tissues, amniotic membrane, and umbilical cord, adult stem 
cells with a self-renewal capacity have been identified within specific niches in most 
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human tissues/organs (21, 99, 103, 108, 111-120). Among them, there are heart, 
brain, adipose tissues, muscles, skin, eyes, kidneys, lungs, liver, gastrointestinal tract, 
pancreas, breast, ovaries, prostate, and testis (21, 99, 103, 111-115, 118, 119, 121-
123). Non-hematopoietic adult stem cells can usually give rise to specialized cells of 
their tissue origin (Fig. 4C). Significant advancements in understanding of stem cell 
biology have provoked great interest and hold high therapeutic promise based on the 
possibility of stimulating their ex vivo and in vivo expansion and differentiation into 
functional progeny that could regenerate the injured tissues/organs in humans (97, 99, 
100, 106, 114, 116, 118, 119, 123-130). Application of adult stem cells in cell-based 
therapy would overcome the ethical concerns that preclude the use of ESC in human 
trials. Nonetheless, in terms of transplantation, the issues of cell integration, survival 
still need to be addressed. 
It is also possible that stem cells could be used to reconstitute more complex 
tissues and organs in vitro, and then transplanted to replace failed organs (Fig. 5). 
Tissue engineering is evolving rapidly and no tissue or organ has been excluded from 
active research. Only a few stem cell generated products, however, have entered 
clinical trials, namely cartilage and skin (131). 
Stem cell treatment might also provide significant help for gene therapy. Gene 
therapy is the introduction of exogenous genetic material to correct or modify the 
function of cells (132, 133). However, high levels of gene expression cannot be 
reached without repeated gene transduction. The application of stem cells may resolve 
that problem. Gene therapy with stem cells is thought to be an ideal treatment strategy 
for many genetic diseases and lung injury (134). In principle, genetic modification of 
small numbers of stem cells produces a stable population of genetically altered cells 
and does not require repeated procedures. However, progress has been limited by the 
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low HSC gene transduction rates. Retroviruses are ideal vectors for integrating target 
genes into the DNA of host cells but it is difficult for them to infect relatively 
quiescent stem cells (132, 134, 135). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Prospects for cell-based therapies. Pharmacological therapy is the application of drugs or 
cytokines to stimulate endogenous stem cells or recruit exogenous stem cells for tissue regeneration 
and repair. Cellular therapy is the utilization of exogenous stem cells to help regeneration and repair 
and tissues or organs for transplantation after in vitro manipulation. Gene therapy with stem cells may 
be used to correct genetic defect. (Adapted from Yen et al., Eur J Clin Invest, 2006). 
 
 
Lung stem cells 
The architecturally complex mammalian lung contains cells from several 
distinct cell lineages, which interact during normal function, making it a difficult 
target for regenerative medicine. It has been reported and frequently cited that the 
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lung contains 40 different cell types (28). Current analyses, however, suggest that this 
number may be a gross underestimate, as new endogenous lung cell populations and 
circulating transient cells found in the lung have since been identified (24, 103, 136-
138). 
The lung is made up of a series of branching airways each smaller than the 
last, terminating in the gas-exchange units, the alveolar sacs. There are approximately 
300 million alveoli in the human lung giving a surface area of about 80 m
2
. The 
airways are lined with a continuous, confluent layer of epithelial tissue that forms a 
continuum from the main pulmonary artery to the capillary network of the distal lung, 
to the pulmonary vein and back to the heart. In between the epithelial and endothelial 
layers is the interstitium, made up of connective tissue cells, which form the 
supporting scaffold for the various lung cell layers.  
The pulmonary tree can be divided into distinct anatomical regions according 
to its epithelial cell types (Fig. 5). The proximal, cartilaginous airways are lined by 
pseudo stratified epithelium containing ciliated and mucous secretory (or goblet) cells 
on the apical surface, with infrequent neuroendocrine cells and the less well 
differentiated basal epithelial cells lying underneath. Ciliated epithelial cells also line 
smaller airways but, rather than goblet cells, the bronchioles posses another cuboidal 
non-ciliated cell type known as the Clara cell, which is important for detoxifying 
inhaled pollutants and secrete Clara cell secretory protein (CCSP). Finally, the alveoli 
are lined by two epithelial phenotypes: flattened squamous (type I) and cuboidal (type 
II) pneumocytes. The type I pneumocyte is the cell type across which gas exchange 
occurs. Its long, thin cytoplasmic extensions present as little a barrier as possible to 
the diffusion of oxygen, while maintaining the integrity of the alveolar wall. The type 
II pneumocyte is far more numerous than type I but makes up only 5% of the alveolar 
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surface area. It is critical for maintaining alveolar homeostasis, clearing the alveolar 
airspace of edema and secreting pulmonary surfactant to lower surface tension and 
prevent airway collapse.  
Cells have been described in the lung that seem to fulfill the criteria for stem 
cells (clonogenicity, the ability to self-renew an the capacity for multilineage 
differentiation), but their identification has been difficult. As well as the problem of 
the structural complexity and cellular heterogeneity of the lung, isolation of 
endogenous stem cells has been hampered by very slow cell turnover; in normal adult 
airways epithelial cell turnover is much lower than that in organs such as the gut and 
the skin. 
 
 
 
 
 
Figure 6. Lung stem cells. Pulmonary 
tree is divided into proximal (trachea) 
and distal airways (terminal bronchi, 
bronchioles and alveoli). Each of these 
compartments is believed to contain 
regional stem cell that in turn get 
activated following local injury. 
Classically, the basal cells of the 
trachea, the Clara cells of the 
bronchiole, bronchoalveolar stem cells 
(BASCs) at the bronchoalveolar duct 
junction and the type II pneumocyte of 
the alveolus are the potential cells 
which can repopulate the injured lung. 
(Lane et al., Regen Med, 2007). 
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The classical view of lung epithelial repair is that there are small populations 
of stem cells deposited throughout the pulmonary tree act to renew the local epithelial 
cell populations. Ciliated cells are widely agreed to be postmitotic and terminally 
differentiated in the adult lung. Therefore, in the proximal airways, the basal cell and 
goblet cell populations are thought to contain stem cells. Basal cells have been shown 
to have the capacity to produce all major cell types in the trachea, including basal 
cells, ciliated cells, goblet cells in the mouse (139-141) and a subset of basal cells in 
human proximal airways (142). Clara cells are the stem cells of distal airways 
epithelium. Variant Clara cells have been reported that express CC10, but are not 
typical Clara cells as they are resistant to airway pollutant, such as naphthalene. They 
reside in neuroepithelial bodies (143-145) and at the bronchoalveolar duct junction 
(146). Ablation of this population eliminates bronchiolar renewal entirely. A 
population expressing markers for both Clara cells and alveolar epithelium has 
recently been identified as a stem cell population for Clara cells and type II 
pneumocytes (103), known as bronchioalveolar stem cells (BASCs). The BASCs 
reside at the bronchoalveolar duct junction and are activated in response to 
bronchiolar and alveolar injury. In the alveoli, type II pneumocytes represent the stem 
cell population, proliferating and transdifferentiating to type I pneumocytes following 
injury of the alveolar wall (147). Unfortunately, type II cells are not sufficient in 
preventing pulmonary disorders (148), suggesting that exogenous cells are indeed 
necessary. Transplantation of alveolar type II epithelial cells into lungs of injured 
mice has been shown to ameliorate the effect of pulmonary fibrosis (149); 
nevertheless a similar approach would have anyway to face the risk of rejection in 
human patients. 
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Extrapulmonary adult stem cells for treatment of lung diseases  
When local tissue-specific stem cells are not sufficient to repair serious injury, 
stem cells may be recruited from other sources to supplement repair. A population of 
multipotent adult progenitor cells (MAPCs) has been isolated from murine bone 
marrow that can differentiate in vitro at the single cell level in all three germ layers 
(150). The mechanism by which these bone marrow-derived stem cells are recruited 
to repair tissue is not known, although tissue injury clearly enhances engraftment (22, 
151-156).  
In 2001, Kotton and colleagues reported engraftment of bone marrow-derived 
cells into the alveolar walls of mice after bleomycin injury (153). Some of these 
engrafted cells had a type I pneumocytes phenotype. Theise and colleagues used a 
model of radiation pneumonitis and whole bone marrow transplantation to show that, 
5 days after transplantation, a sub-population of type II pneumocytes in the irradiated 
lungs were of bone marrow origin (156). Bone marrow-derived cells engrafted as 
alveolar epithelium have been reported in irradiated lungs as long as 11 months after 
transplantation (134). MSCs isolated from bone marrow engraft in distal airways as 
epithelial-like cells to a greater degree after lung injury than in control mice (155). 
Circulating cells engraft in the lung as fibroblast-like interstitial cells and type I 
alveolar epithelium following radiation (151). Bone marrow-derived cells engraft as 
epithelium and endothelium in the alveolar walls of lipopolysaccharide-treated mice 
after whole bone marrow transplantation (157) (Fig. 7). 
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Figure 7. Extrapulmonary stem cells for treatment of lung disorders. Following injury, bone marrow-
derived cells such as HSCs or MSCs can repopulate pulmonary epithelium; on the other hand, bone 
marrow-derived fibrocytes can migrate to lungs and contribute to the progression of fibrosis. 
 
 
Recent studies have raised questions about the aforementioned results (158-160) and 
no clear consensus exists on the degree of lung chimerism following bone marrow 
transplantation. Engraftment of donor cells into epithelium and differentiation into 
epithelial cells has been shown to be very limited or to not occur at all (161, 162). The 
conflicting results could be the product of the differing injury models used. The 
differences in the data are likely due to differences in donor cell type, injury models, 
time after bone marrow transplantation, and detection techniques. In fact, Herzog and 
colleagues proved that a threshold of injury was necessary for bone marrow-derived 
cells to engraft in the lung (163). In addition, controversies arose about the 
functionality of bone marrow cells; some circulating bone marrow-derived cells seem 
to be disease-causing (151) and others appear to be protective (154). Until 
reproducible isolation, injury and transplantation procedures are established across 
laboratories, the controversy regarding the contribution of circulating cells to lung 
repair and their therapeutic potential will continue (164). 
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To date, investigation of human lung has either found no engraftment of bone 
marrow cells within the pulmonary epithelium, or has shown that it occurs only at a 
very low rate (165-171). These studies have been fraught with technical problems, not 
only because of the need to rely on the colocalization of histological markers, but also 
because of the scarcity and poor quality of appropriate human lung tissue samples. 
Nevertheless, if circulating cells can be recruited to the damaged pulmonary 
epithelium promoting tissue repair, this could be of major clinical interest. 
 
 
Prominin-1/CD133 as a marker of stem and progenitor cells 
Since its discovery 10 years ago, prominin-1 (alias CD133) has received 
considerable interest because of its expression by several somatic stem and progenitor 
cells originating from various sources, including the neural and hematopoietic 
systems, and in embryonic stem cell-derived progenitors (172-174). Murine prominin-
1 was identified as a novel marker of neuroepithelial cells, primary progenitor cells of 
the mammalian central nervous system (172), whereas its human counterpart 
constituted a new hematopoietic stem and progenitor cell (HSPC) marker (initially 
referred to as AC133 antigen) (173, 175). As a cell surface marker, prominin-1 is now 
used for somatic stem cell isolation (173, 176-178). CD133
+
 stem and progenitor cells 
might become clinically important, particularly with regard to brain injury/disease and 
bone marrow transplantation. It is important to note that, although various stem and 
progenitor cells express prominin-1, its expression is not limited to primitive cells. 
For instance, prominin-1 is detected in several epithelia in adult mice and humans 
where it appears to be restricted to the apical (luminal) side (172, 179-182). 
Additionally, prominin-1/ CD133 is often used for the identification and isolation of 
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putative cancer stem cell populations from malignant tumors of brain (183, 184), 
prostate (185), liver (186, 187), pancreas (188), lung (189), and colon (190-192). Its 
expression in cancer stem cells has broadened its clinical value, as it might be useful 
to outline new prospects for more effective cancer therapies by targeting tumor-
initiating cells.  
Cell biological studies of this molecule have demonstrated that it is 
specifically concentrated in various membrane structures that protrude from the 
planar areas of the plasmalemma. Prominin-1 binds to the plasma membrane 
cholesterol and is associated with a particular membrane microdomain in a 
cholesterol-dependent manner. Although its physiological function is not yet fully 
determined, a recent finding has shown that transgenic mice carrying human mutation 
for the prominin-1 gene (PROM1) undergo progressive photoreceptor degeneration in 
the retina consistent with that found in human patients (193), suggesting a functional 
role for prominin-1. 
Prominin-1 is expressed on a subpopulation of CD34
+
 HSPCs derived from 
various sources including fetal liver and bone marrow, adult bone marrow, cord blood 
and mobilized peripheral blood (173, 175, 194). Interestingly, an immunomagnetic 
selection of CD133
+
 HSPCs allowed the enrichment of a sufficient amount of cells to 
perform hematopoietic stem cell transplantation (195), and pilot trials with leukemic 
children have proven the feasibility of CD133
+
 selection for allogeneic transplantation 
(196, 197). Other studies have shown the successful transplantation of 
haploidentically mismatched peripheral blood stem cells using CD133
+
 purified stem 
cells (198). Thus, the immunomagnetic isolation procedure of HSPCs based on 
prominin-1 appears to be an interesting alternative to CD34 (199). Moreover, 
accumulating studies illustrate that prominin-1/CD133
+
 progenitor cells can exert 
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beneficial effects in treating of different pathological disorders, including cardiac and 
hepatic malignancies (96, 97, 125, 200-205). 
 
 
Nitric oxide and lung injury 
NO is a free radical produced in mammalian cells from the oxidation of L-
arginine by three isoforms of an enzyme known as NO synthase (NOS), which occurs 
in three major isoforms: neuronal (nNOS or type I), inducible (iNOS or type II) and 
endothelial (eNOS or type III) (206-208). Neuronal and endothelial isoforms are 
constitutively expressed and are referred to as cNOS. 
Nitric oxide is a pleiotropic mediator, which acts in a variety of physiological and 
pathophysiological processes (209-212). NO has a half-life of only a few seconds in 
vivo, but its solubility in both aqueous and lipid media is probably responsible for its 
pleiotropic effects in the cells. The constitutively expressed enzyme (cNOS) are 
calcium-dependent, release NO under physiological condition in various cells, 
including endothelial cells and neurons, and NO released by these isoforms are 
involved in the regulation of blood pressure in organ blood flow distribution, in the 
inhibition of the adhesion and activation of platelets and polymorphonuclear 
granulocytes and in neuronal transmission. Mice that overexpress eNOS in the lung 
are protected from ventilator-induced lung injury (213). 
The inducible isoform of NOS (iNOS) is calcium-independent and can be 
induced by proinflammatory agents, such as endotoxins (bacterial lipopolysaccharide, 
LPS), interleukin-1#, tumor necrosis factor-" (TNF-") and interferon-! (IFN-!), in 
endothelial and smooth-muscle cells, in macrophages and in other cell types (208-
212). 
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NO is well known to play critical roles in homeostasis, regulation of 
inflammatory processes, suppression of apoptosis and T-cell proliferation (206, 214-
220). Moreover, current levels of evidence suggest a protective role for NO in various 
lung disease models (221-225). 
Recent clinical trials using low-dose inhaled NO revealed benefits in 
prevention and alleviation of acute lung injury in adults (226), hypoxemic respiratory 
failure in infants and children (227) and chronic lung disease in neonatal infants 
(228), whose lungs are exposed to high oxygen and at risk of hyperoxic damage. 
NO is a potent mediator of alveolarization and lung growth (229, 230). 
Whereas the normal response to lung injury is migration and proliferation of type II 
pneumocytes to reestablish an intact epithelial lining, the chronic and repetitive injury 
that culminates in fibrotic lung disease promotes hyperplasia and dysplasia of alveolar 
epithelial cells (AEC). Injured and activated AEC then participate in aberrant 
cytokine signaling that perpetuates the fibrotic response. Of particular recent interest 
is the possibility that AEC contribute directly to fibrosis through epithelial-
mesenchymal transition (EMT) to a myofibroblast-like phenotype. Although 
myofibroblasts are integral to normal repair mechanisms, the persistence of the 
myofibroblasts beyond a period of normal repair has been associated with ECM 
deposition, structural remodeling, and destruction of alveocapillary units. Recent 
studies (231-233) have demonstrated alveolar EMT both in vitro and in vivo and have 
shown that the majority of myofibroblast-like cells after experimental injury are the 
result of alveolar EMT. There is mounting evidence that alveolar EMT is primarily 
mediated by local production and activation of transforming growth factor (TGF)-#1 
(231, 232). Additionally, TGF-#1 down-regulates NOS expression in a variety of non-
pulmonary cell types (234-236), and NO production is dramatically increased in TGF-
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#1 null mice (237), indicating a reciprocal relationship between TGF-#1 and NO. In 
fact, recent evidence have illustrated that NO can play an important role in prevention 
of EMT in alveolar epithelial cells following bleomycin (238), suggesting a 
regulatory function in the context of lung injury. 
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Aim of the thesis 
 
Idiopathic Pulmonary Fibrosis is a chronic, progressive and often fatal form of 
interstitial lung disease. IPF continues to pose a major clinical challenge since an 
effective therapeutic regimen has yet to be developed. My aim was to identify a 
population of stem/progenitor cells capable to suppress pulmonary inflammation and 
to mediate regeneration of injured lung tissue. I hypothesized that under certain 
conditions it must be possible to expand these cells from dissected adult lungs. 
Therefore, I planned to establish an efficient method for the isolation and generation 
of high numbers of progenitor cells and to address their regenerative potential in vitro 
and in vivo. As in vivo model I chose the mouse model of BLM-induced lung injury.  
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Materials and Methods 
 
Mice: C57Bl/6 mice and C57Bl/6-GFP transgenic mice (GFP under the control of "-
actin promoter) were purchased from Jackson Laboratory. iNOS
-/-
 C57Bl/6 mice were 
kindly provided by Dr. Adrian J. Hobbs, Wolfson Institute for Biomedical Research, 
University College London. All mice were housed in optimized hygienic rooms (in 
accordance with the guidelines of the Department of Biomedicine at the University 
Hospital Basel) and received acidified (pH 2.5) water and sterile food. Newborn male 
and female mice were separated 3 weeks after birth in sterilized cages covered by a 
special protecting filter. No more than 5 mice were put together into each cage. All 
animal experiments were conducted in accordance with institutional guidelines and 
Swiss federal law and were approved by the local authorities. 
 
Generation of bone marrow chimera: 5-7 week old C57Bl/6 CD45.2 mice were 
lethally irradiated with two doses of 6.5 Gy (4 hours between each round of 
irradiation) using a Gammatron (Co-60) system and reconstituted with 2x10
7
 donor 
bone marrow cells from C57Bl/6 GFP or C57Bl/6 CD45.1 mice. Cells were 
resuspended in 200 $l of sterile PBS and administrated intravenously into the tail 
vein. After reconstitution, all mice received prophylactic antibiotics (0.2% Bactrim, 
Roche, Basel, Switzerland) in the drinking water. 
  
Bleomycin-induced lung fibrosis: 7-9 week old male C57Bl/6 mice were 
anesthetized using Ketalar (75 mg/kg; Parke-Davies, Zürich, Switzerland) and 
Xylasol (10 mg/kg; Gräub AG, Bern, Switzerland) resuspended in 0.9% NaCl by 
intraperitoneal injection. Individual mice were fixed on an oblique plane and their 
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throat was illuminated with a focused cold light lamp (KL 1500 LCD, Carl Zeiss, 
Germany) and the tongue of the animal was pulled out of its mouth (Fig. 8A, B). 
Instillation of 0.05 U/mouse bleomycin (Blenoxane, Axxora-Alexis, San Diego, CA, 
USA) dissolved in 50 $l of sterile PBS was done under view, directly into the tracheal 
lumen. Control animals received the same volume of PBS. Two hours after PBS/BLM 
instillation, the animals received intratracheally either 2 x 10
5
 prominin-1
+
 cells 
resuspended in 50 $l of PBS or PBS alone. 
 
 
Figure 8. Intratracheal instillation is performed using a cold light lamp (A); the tongue of the mouse is 
pulled out and bleomycin, cells or PBS are injected into the tracheal lumen (B). 
 
Isolation and expansion of prominin-1
+
 cells: Lungs of 7-9 week old C57Bl/6 mice 
were perfused by injection of 5-10 ml of ice cold PBS through the right ventricle. 
Next, lungs were excised, separated from the trachea and the main bronchi, manually 
dissected into small pieces with carbon steel surgical blades (Swann-Morton), and 
digested for 90 min at 37°C in 15 ml of GKN (11
 
mM D-glucose (Sigma), 5.5 mM 
KCl (Fluka), 137 mM NaCl (Roth), 25 mM Na2HPO4 (Fluka), 5.5
 
NaH2PO4·H2O 
(Fluka)) containing 10% FCS,
 
1.8 mg/ml collagenase type 4 (Worthington 
Biochemical. Corp., Freehold, NJ, USA) and 0.1
 
mg/ml DNAse I (Sigma). The cell 
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suspension was filtered through 70 $m nylon mesh and washed with GKN containing 
10% FCS. Cells were resuspended in IMDM (Iscove's Modified Dulbecco's Medium, 
Sigma) containing 2% FCS, 100 $M "-mercaptoethanol (Gibco), 100 U of penicillin 
and 100 µg of streptomycin/ml (Pen/Strep, Gibco), 2mM L-glutamine, 25 mM Hepes, 
and plated at 5 x 10
6
 cells into 6 cm diameter tissue culture dishes. Cells were 
incubated at 37°C in a humidified atmosphere containing 5% CO2. The medium was 
changed 2-3 times a week. Non-adherent cells were removed 48-72 hours after 
plating. Culture of lung homogenates gave rise to two main populations consisting in 
a round cell population and a fibroblast-like cell population that worked as a feeder 
layer. 
 
Magnetic Activated Cell Sorting (MACS): After 3-4 weeks cells were removed 
with cell scrapers, washed, and filtered through 40-$m nylon mesh. Then, cells were 
stained for 30 min at 4°C with an anti-prominin-1 PE antibody 1:200 (eBiosciences 
San Diego, CA, USA), in MACS buffer (PBS supplemented with 2 mM EDTA and 
1% FCS) and isolated using anti-PE antibodies coupled to magnetic beads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions 
(purity > 95%).  
 
In vitro differentiation: For alveolar epithelial cell differentiation, MACS sorted 
prominin-1
+
 cells were cultured two weeks onto sterile 0.2% gelatin-coated round 
cover slips (12 mm diameter, Menzel-Gläser, Germany) in 24 well plates in the 
presence of modified Small Airway Growth Medium (SAGM) (239) consisting of a 
basal medium (Small Airway Basal Medium, SABM, Cambrex, East Rutherford, NJ, 
USA) supplemented with 0.5 mg/ml BSA, 0.5% FCS, ITS supplement, 30 $g/ml 
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bovine pituitary extract, 0.5 $g/ml epinephrine, 6.5 ng/ml triiodothyronine, 0.1 ng/ml 
retinoic acid, 0.5 $g/ml hydrocortisone (all Sigma) and 1 ng/ml EGF (PeproTech, 
UK). For macrophage differentiation, prominin-1
+
 cells were cultured two weeks in 
the presence of M-CSF (10 ng/ml) added to IMDM 2% FCS. For phagocytosis assay 
Escherichia coli BioParticles Alexa Fluor 488-conjugated (Molecular Probes, 
Invitrogen, Carlsbad, CA, USA) were used according to the manufacture instruction. 
To induce fibroblast differentiation, prominin-1
+
 cells were kept two weeks in the 
presence of TGF-#1 (10 ng/ml) (PeproTech, UK) added to IMDM 2% FCS. 
 
Single cell-derived colony assay: prominin-1
+
 cells were sorted from GFP culture 
and plated in presence of non-GFP cells in 24 well/plates. Up to 5 GFP
+
/prominin-1
+
 
cells were co-cultured with 2 x 10
4
 GFP negative cells. After 2-3 weeks single cell-
derived colonies were selected, removed, washed and transferred into new wells to 
induce in vitro cell differentiation. 
 
Flow cytometry: Cells were filtered through 40-$m nylon mesh, stained for 30 min 
on ice with the appropriate antibodies diluted in FACS buffer (PBS supplemented 
with 2 mM EDTA and 0.5 BSA%), and analyzed on a BD FACSCalibur
TM
 (BD 
Biosciences, San Jose, CA, USA) and a CyAN (Dako-Cytomation, Carpinteria, CA, 
USA) using FlowJo 8.7.3 software (TreeStar, Ashland, OR, USA). The following 
antibodies and dilutions were used: Primary antibodies: anti-prominin-1-PE 1:200 
(eBioscience), anti-CD11b-APC 1:400, anti-CD11c FITC 1:200, anti-CD45.1 FITC 
1:200, anti-CD45.2 PerCP Cy5.5 1:200, anti-CXCR4-FITC 1:200, anti-MHC II 
1:1000, anti-Gr1 FITC 1:500 (BD Bioscience, San Jose, CA, USA), goat anti-Sca-1 
1:200 (R&D Systems, Abingdon, UK), biotin anti-c-kit 1:200, biotin anti-CD14 
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1:200, biotin anti-CD34 1:200, biotin anti-CD45 1:200, rat anti-CD31 1:400, 
(eBioscience, San Diego CA, USA), rabbit anti-collagen I (Rockland, Gilbertsville, 
PA, USA). Secondary antibodies: Alexa Fluor 488 donkey anti-goat 1:200, Alexa 
Fluor 488 chicken anti-rabbit 1:200, Alexa Fluor 488 donkey anti-rat 1:100 
(Molecular Probes, Invitrogen, Carlsbad, CA, USA) and streptavidin-APC 1:200 (BD 
Bioscience, San Jose, CA, USA). Cells from adult mouse lungs were sorted with 
inFlux Cell Sorter (Cytopeia, Seattle, WA, USA). 
 
Immunofluorescence: Cells were cultured on 0.2% gelatin-coated cover slips and 
fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. After 
blockade of non-specific binding with 10% FCS in PBS (30 min at room 
temperature), cells were stained for 1 hour at 37°C with the appropriate primary and 
secondary antibodies. Following nuclear staining with DAPI (10 min at room 
temperature, no-light exposed), cover slips were washed with distilled water and 
mounted with Fluorescent Mounting Medium (Dako Corporation, Carpinteria, CA, 
USA).  
Paraffin sections: Paraffin-embedded lung sections were deparaffinized in two 5-min 
exposures to xylene; rehydrated
 
in decreasing ethanol concentrations of 100%, 95%, 
70%, and 50%;
 
and subsequently washed in distilled water and PBS. 
Frozen sections: Lung tissues were separated in single main lobes, placed in base 
mould disposable (Kaltek, Padova, Italy) and snap-frozen in O.C.T.
TM
 Compound 
(Tissue-TeK®, Sakura, Netherlands) onto dry ice. Frozen samples were stored at -
70°C until use. Serial 10-µm sections were cut with Microm HM 560 cryostat and 
thaw-mounted onto SuperFrost® microscope slides (76 x 26 mm, Menzel-Gläser, 
Germany). Frozen sections were initially stained with appropriate antibodies; next, 
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sections were fixed with 4% paraformaldehyde and then non-specific binding was 
neutralized with 10% FCS in PBS.  
Primary antibodies: rat anti-prominin-1-PE 1:200 (eBioscience, San Diego CA, 
USA), CD45.2 FITC 1:200 (BD Bioscience, San Jose, CA, USA), rabbit polyclonal 
anti-surfactant protein-C 1:400 (SP-C, Chemicon, Temecula, CA, USA), rabbit anti-
collagen I 1:200 (Rockland Immunochemicals, Gilbertsville, PA, USA), mouse anti-
"-tubulin IV 1:400 (Sigma), rabbit anti-fibronectin 1:400 (Sigma), rabbit polyclonal 
anti-aquaporin-5 1:300 (Calbiochem, La Jolla, CA, USA), biotin anti-CD14 1:200 
(eBioscience). Secondary antibodies: Green-fluorescent Alexa Fluor 488 rabbit anti-
GFP 1:200, Alexa Fluor 488 chicken anti-rabbit 1:200, Alexa Fluor 546 goat anti-
rabbit 1:400, Alexa Fluor 488 goat-anti mouse 1:200 (Molecular Probes, Invitrogen, 
Carlsbad, CA, USA), streptavidin-PE 1:200, streptavidin-PE Cy7 1:200 (BD 
Bioscience, San Jose, CA, USA). Cells and sections were stained 10 min with 4’,6-
diamidino-2-phenylindole (DAPI) to visualize cell nuclei. Samples were examined 
with Olympus BX61 Fluorescence Microscope ad with Olympus IX50 Inverted 
Microscope. Samples were stored at 4°C. 
 
Histology: Animals were sacrificed on selected days after BLM instillation. Lungs 
were perfused, removed, fixed in 4% formaldehyde and cut in 5 $m sections. Samples 
were stained with Hematoxylin-Eosin (H&E); Masson's trichrome or Chromotrop 
Anilinblue (CAB) stain were used to visualize collagen depositions. Staining 
procedures were performed by the laboratories of Institute of Pathology, University of 
Basel. 
 
Bronchoalveolar Lavage (BAL): Mice were sacrificed by intra-peritoneal injections 
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of Pentothal
®
 (Abbott Laboratories, North Chicago, IL, USA). The trachea was 
exposed and cannulated with a size 20G sterile catheter (OPTIVA
®
 2, Medex, 
Rossendale, UK). Lavage was performed a total of 3-4 times by repeated flushing 
with 1 ml of ice-cold PBS. The BAL fluid (BALF) was stored on ice until 
centrifugation (4 min at 1500 rpm at 4°C). Collected cells were resuspended in 500 $l 
of PBS and counted. Next, cells were centrifuged again and re-suspended in 50-60 $l 
of PBS; then, were cyto-spun onto slides (7 min at 700 rpm), Diff-Quik stained 
(according to the manufacturer’s protocol), and analyzed under a light microscope for 
cell differentials.  
 
Alveolar macrophages isolation: BALFs from several mice were pooled and 
centrifuged at 300g for 10 min. The resulting pellet was re-suspended in RPMI-1640 
medium (Gibco) supplemented with 10% FCS and incubated for 1 hour at room 
temperature on 10 cm diameter plastic dishes. Non-adherent cells were washed off 
with PBS and the adherent macrophages were collected. Cells were then removed 
with cell scraper, counted and transferred into 96 well plates for co-culture 
experiments. 
 
Blood collection.  Blood was collected via the inferior vena cava after opening the 
body cavity. A 1-mL syringe containing EDTA was used to bleed
 
the mice. Cells 
were separated from erythrocytes using Lympholyte-M (Cedarlane Laboratories Ltd, 
Hornby, Canada) according to the manufacturer's instructions. 
 
Co-culture experiments: MACS sorted prominin-1
+
 cells were irradiated (2000 rad) 
and cultured in RPMI with 10% FCS (Gibco) 100 $M "-mercaptoethanol (Gibco), 
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100 U of penicillin and 100 µg of streptomycin/ml (Pen/Strep, Gibco), in 96-well 
plates in the presence of alveolar macrophages (AM) at a ratio of 1:2. Cells were 
stimulated for 24 h with LPS (0.1 $g/ml) and IFN-# (50 ng/ml). AM proliferation was 
measured by [
3
H]Thymidine incorporation (0.5 µCi/well for the last 8 hours). Nitrite 
(NO2
-
) levels reflecting NO production in culture supernatants were assessed using 
the Griess Reagent System (Promega, Madison, WI, USA).  
CD4
+
 T cells were MACS sorted from BLM-treated animals and cultured for two 
days in RPMI with 10% FCS. 96 well plates were previously coated for two hours 
with anti-CD3/anti-CD28 antibody (1 $g/ml). 5 x 10
4
 T cells were co-cultured with 
titrating amount of prominin-1
+
 cells. Cell proliferation was measured by 
[
3
H]Thymidine incorporation.
 
 
Real Time quantitative-PCR and Reverse Transcriptase-PCR Analysis: RNA 
was isolated using TRIzol™ Reagent (Invitrogen, Carlsbad, CA, USA) from total 
lung tissue according to the manufacturer’s recommendations. First strand cDNA 
synthesis was performed as following: RNA (2 $g) was incubated with oligo(dT)
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for 5 min at 70°C and chilled on ice. 5x reaction buffer, 10mM 4dNTP mix, RNase 
inhibitors and RevertAID™ M-MuLV Reverse Transcriptase (Fermentas, St. Leon-
Rot, Germany) were added and the reaction mixture was incubated for 60 min at 
42°C. For RT-PCR the following primers were used: AQP5 Fw 5'-GGC CAC ATC 
AAT CCA GCC ATT A-3’, Rw 5'-GGC TGG GTT CAT GGA ACA GCC-3’; "-
tubulin Fw 5’-GGA ACA TAG CCG TAA ACT GC-3’, Rw 5’-TCT ACT GTG CCT 
GAA CTT ACC-3’; CC10 Fw 5’-CGC CAT CAC AAT CAC TGT GGT CA-3’, Rw 
5’-GAG GGT ATC CAC CAG TCT CTT CA-3’; E-cadherin Fw 5’-ACG TAT CAG 
GGT CAA GTG CC-3’, Rw 5’-CCT GAC CCA CAC CAA AGT CT-3’; Islet-1 Fw 
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5’-GTT TGT ACG GGA TCA AAT GC-3’, Rw 5’-ATG CTG CGT TTC TTG TCC 
TT-3’; Keratin 5 Fw 5’-ACC CTT GTT CCA CGG AAT GCA A-3’, Rw 5’-AAA 
GCA CAG TTA AGA CCA GAA AC-3’; Nanog Fw 5’-AGG GTC TGC TAC TGA 
GAT GCT CTG CA-3’, Rw 5’-CAA CCA CTG GTT TTT CTG CCA CCG-3’; Oct4 
Fw 5’-GTG GAT TCT CGA ACC TGG CT-3’, Rw 5’-GTC TCC AGA CTC CAC 
CTC AC-3’; SP-C Fw 5’-TAT GAC TAC CAG CGG CTC CT-3’, Rw 5’-GTT TCT 
ACC GAC CCT GTG GA-3’. The primers used for quantitative Real Time PCR are 
listed in Table 1. Real-time PCR was performed using a 7500 Fast Real time PCR 
System (Applied Biosystems, Foster City, CA, USA) in the presence of SYBR-green 
(Applied Biosystems); GAPDH was used as internal control. Amplification 
conditions were as following: 50°C (2 min); 95°C (10 min); 95°C (15 s), 60°C (1 
min), 40 repetitions. Specificity of each reaction was ascertained by performing the 
Melt procedure (60–95°C; 1°C/15 sec) after completion of the amplification protocol, 
according to the manufacturer's instructions. Relative gene expression was analyzed 
using the 2
-%%Ct
 method. 
 
Statistics: Normally distributed data, such as proliferation responses and cytokine 
levels, were compared using the Student t test. Statistical analysis was conducted 
using Prism 4 software (GraphPad Software). p < 0.05 was considered to be 
statistically significant. 
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Table 1. Primers used in Real Time quantitative-PCR. 
Gene Forward Primer Reverse primer 
GAPDH  CCTGCACCACCAACTGCTTA TCATGAGCCCTTCCACCATG 
iNOS CAGCTGGGCTGTACAAACCTT TGAATGTGATGTTTGCTTCGG 
IL-4 ACAGGAGAAGGGACGCCAT GAAGCCCTACAGACGAGCTCA 
IL-6 TGTATGAACAACGATGATGCACTT GGTACTCCAGAAGACCAGAGGAAAT 
IL-13 CGCAAGGCCCCCACTAC AAAGTGGGCTACTTCGATTTTGG 
IFN-#  TGGAGGAACTGGCAAAAGGAT GCCTGATTGTCTTTCAAGACTTCAA 
TNF-!  CCCAGACCCTCACACTCAGATC CCTCCACTTGGTTTGCT 
CCL2 CATCACTGAAGCCAGCTCTCTCT GCAGGCCCAGAAGCATGA 
MIP-1!  TTTTGAAACCAGCAGCCTTTG TCTTTGGAGTCAGCGCAGATC 
MCP-5 AGAATCACAAGCAGCCAGTGTC GTCAGCACAGATCTCCTTATCCAGT 
TGF-!1 CAACGCCATCTATGAGAAAACC AAGCCCTGTATTCCGTCTCC 
Fibronectin  TACCAAGGTCAATCCACACCCC CAGATGGCAAAAGAAAGCAGAGG 
Col-I GATGACGTGCAATGCAATGAA CCCTCGACTCCTACATCTTCTGA 
SDF-1!  CGTGAGGCCAGGGAAGAG TGATGAGCATGGTGGGTTGA 
CCL21/SLC GGCAAAGAGGGAGCTAGAAAACA TGGACGGAGGCCAGCAT 
MMP-9 CCTGGAACTCACACGACATCTTC TGGAAACTCACACGCCAGAA 
KC/CXCL1 TGCACCCAAACCGAAGTCAT GGAGCTTCAGGGTCAAGGC 
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Results 
 
Expansion of prominin-1
+
 progenitor cells 
Several lines of evidence suggest that activation of tissue resident progenitor 
cells represents an injury-triggered process (103, 240). Thus, we hypothesized that 
dissection of pulmonary tissue creates a specific “injured” microenvironment 
promoting the expansion of progenitor cells with specific differentiation capacity. We 
therefore separated distal airways from the trachea and main bronchi and dissected 
into small pieces (Fig. 9A). In fact, the culture of lung homogenates gave rise to a 
population of small, round, semi-attached cells, growing on a feeder layer (Fig. 9B, 
C). Immunohistochemistry revealed that round cells were all positive for prominin-1, 
whereas feeder layer cells were positive for Col I (Fig. 9D). 
 
 
 
 
Figure 9. Characterization of lung explants. Distal part of adult mouse lungs (A) were cut, digested 
and plated in 6 cm dishes at a concentration of 5 x 106 cells/dish. Passage 0 cultures after 3 days exhibit 
a heterogeneous population (B); after 14 days a population of rounded, semi-adherent cells expanded 
growing on feeder layer cells (C). Immunohistochemistry showed that all round cells were positive for 
prominin-1 (red), but not Col I (green) (D). DAPI (blue) was used to visualize cell nuclei. Bars = 30 
$m. 
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Characterization of prominin-1
+
 progenitor cells 
FACS analysis revealed that the vast majority of prominin-1
+
 cells co-
expressed markers characteristic of stem cells such as Stem Cell Antigen-1 (Sca-1) 
(Fig. 10A), c-kit (CD117) (Fig. 10B), Chemokine Receptor type 4 (CXCR4) (Fig. 
10C), as well as the hematopoietic antigen CD45 and CD11b (Fig. 10D, E). In 
contrast, prominin-1
+
 cells did not show co-expression with endothelial markers such 
as CD34 and CD31 (Fig. 10F, G), fibrocyte marker Col I (Fig. 10H), macrophage 
marker CD14 (Fig. 10I), dendritic cell marker CD11c (Fig. 10J), granulocyte marker 
Gr1 (Fig. 10K), and Major Histocompatibility Complex class II (MHC II) (Fig. 10L). 
 
 
 
 
Figure 10. Characterization of prominin-1+ progenitors by FACS. (A-L). Prominin-1+ cells were 
positive for stem cell (A-C) and hematopoietic markers (D-E), but were negative for mature markers 
(F-L).  
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Prominin-1
+
 progenitor cells were then purified by cell sorting and further 
analyzed. RT-PCR revealed that prominin-1
+
 cells were negative for bronchial (Clara 
Cell 10-kd protein, CC10), alveolar type I (aquaporin-5, AQP-5), alveolar type II 
(surfactant protein-C, SP-C) and epithelial (E-cadherin and keratin 5, K5) genes (Fig. 
11A), but expressed genes characteristic for stem and progenitor cells (Islet-1, Nanog, 
but not Oct4) (Fig. 11B). 
 
 
 
 
Figure 11. Characterization of prominin-1+ cells by RT-PCR. Prominin-1+ cells showed no expression 
of lung epithelial markers (CC10, SP-C, AQP-5, K5, E-cadherin) (A); whole lung tissue was used as 
positive control. In contrast, expression of genes characteristic for stem and progenitor cells (Islet-1, 
Nanog) was detected. cDNA from mouse embryonic stem cells was used as positive control (B). 
Amplification of reactions without cDNA was used as negative control. 
 
 
Density is critical for maintenance of prominin-1
+
 cell phenotype 
Next we sorted prominin-1
+
 cells and plated them at different densities in 6 
well plates. Cells were cultured at densities between 0.25 x 10
4
 (2.5K) and 6 x 10
4
 
(60K) cells/cm
2
 (Fig. 12A-F). Morphological analysis by microscope showed that 
after 3 weeks prominin-1
+
 cells plated at high density kept a round phenotype (Fig. 
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12J-L), whereas cells plated at low density became flat and only occasionally round 
cells were found (Fig. 12G-I). These data illustrated that density is definitely crucial 
for maintenance of prominin-1
+
 round cell phenotype. 2 x 10
4
 (20K) was identified as 
the minimal density necessary for prominin-1
+
 cells to grow in vitro. 
 
 
 
 
 
 
Figure 12. Density-dependent expansion of prominin-1+ cells. MACS sorted prominin-1+ cells plated 
at different densities (A-F) after 3 days. After two weeks cells plated at high density kept round cells 
phenotype (J-K), but not cells cultured at low density (G-I). (6 x 104 cells/cm2 = 57.6 x 104 cells). Bars 
= 30 $m. 
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Prominin-1
+
 cells show bone marrow origin 
As shown in the Figure 10, nearly all prominin-1
+
 cells co-expressed 
hematopoietic markers. To confirm the bone marrow origin of these cells, we 
generated chimeric mice. C57Bl/6 CD45.2 mice were lethally irradiated and 
reconstituted with bone marrow cells from or C57Bl/6 CD45.1 mice. FACS analysis 
of lungs of C57Bl/6 mice showed presence of two CD45.2
+
 populations (Fig. 13A). 
Three weeks after bone marrow transplantation CD45.1
+
 cells replaced nearly all 
CD45.2
+
 cells (Fig. 13B). 
Next, we dissected lung tissues from chimeric mice and expanded prominin-1
+
 
lung-derived progenitors as described. As illustrated in Fig. 13C, nearly all prominin-
1
+
 cells were CD45.1 positive, indicating clearly that prominin-1
+
 cells are of bone 
marrow origin. These data were confirmed by culturing chimeric lungs from mice 
reconstituted with donor GFP cells. In fact, immunohistochemistry revealed that 
nearly all prominin-1
+
 cells were also GFP positive (Fig. 13D). 
 
 
 
Figure 13. Bone marrow origin of prominin-1+ cells.  FACS analysis of lungs from C57Bl/6 CD45.2 
mice lethally irradiated and reconstituted with CD45.2+cells (A) or CD45.1+cells (B) 3 weeks after 
bone marrow transplantation. FACS (C) and immunohistochemistry (D) demonstrated that prominin-1+ 
cells expanded from chimeric lungs were of bone marrow origin. Prominin-1 (red), GFP (green), DAPI 
(blue). Bar = 30 $m. 
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In vitro multipotent capacity of prominin-1
+
 cells 
Bone marrow cells are well known to show high plasticity. We therefore, 
addressed the potential of prominin-1
+
 progenitors to differentiate in vitro into various 
cell phenotypes. 
To induce alveolar epithelial differentiation, sorted prominin-1
+
 cells were 
cultured for two weeks in modified Small Airway Growth Medium (SAGM) (Fig. 
14A). Immunofluorescence microscopy showed the expression of surfactant protein-C 
(SP-C) (Fig. 14B), which is specific for pulmonary type II cells. As illustrated in Fig. 
14C, all cells differentiating into type II cells lost expression of prominin-1. RT-PCR 
confirmed the expression of SP-C, but not of CC10 and AQP5, which are 
characteristic for bronchial and alveolar type I epithelial cells, respectively (Fig. 14E).  
To induce fibroblast differentiation prominin-1
+
 cells were cultured two weeks 
in the presence of TGF-#1 (10 ng/ml). After 3 days cells changed phenotype, 
acquiring an elongated, bipolar phenotype (Fig. 14F); two weeks after differentiation 
induction, culture contained mostly cells with fibroblast-like phenotype (Fig. 14G). 
Prominin-1
+
 cells were all positive for fibronectin (Fig. 14H) and Col I (Fig. 14I), 
fibroblast-specific marker. In addition, flow cytometry confirmed that, in presence of 
TGF-#1, prominin-1 expression was lost (Fig. 14L, M).  
After two weeks in culture with M-CSF (10 ng/ml), prominin-1
+
 cells 
acquired large and flat morphology; microscope analysis revealed that more than 80% 
of cells showed phagocyted bacteria within their cytoplasms (Fig. 14N, green). 
Moreover, immunohistochemistry (Fig. 14O) and flow cytometry (Fig. 14P) showed 
that more than 40% of cells were positive for the macrophage marker CD14. 
 
 46 
 
 
 
Figure 14. In vitro differentiation capacity of prominin-1+ cells. Lung explants were cultured for 3-4 
weeks and prominin-1+ cells were MACS sorted. Phase contrast micrograph of prominin-1+ cells 
incubated for 2 weeks in SAGM (A) and stained for surfactant protein-C (SP-C, red) (B). Expression of 
prominin-1 was lost after differentiation (C).; cells stained with rabbit IgG isotype control (D). RT-
PCR confirmed expression of SP-C type II cell specific gene, but no other lung epithelial genes (E). In 
the presence of TGF-#1, prominin-1+ cells acquired an elongated, flat phenotype (F, G). All cells were 
positive for fibronectin (H, red) and Col I (I, green) and lost prominin-1 expression (L, M). In the 
presence of M-CSF, prominin-1+ cells differentiated into functional macrophages phagocyting E. coli 
bioparticles (N, O, green) and acquired CD14 expression, as illustrated by immunohistochemistry (O, 
red) and flow cytometry (P). Bars = 30 $m. 
 
 
Given the bone marrow origin of prominin-1
+
 cells, we wanted to confirm that 
cells expanded from chimeric mice had the same differentiation potential. Therefore, 
we expanded prominin-1
+
 cells from GFP chimeric lungs. Cells were purified using 
magnetic beads and cultured in presence of appropriate media and factors. 
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Prominin-1
+
 cells cultured in presence of SAGM differentiated into alveolar 
type II cells and showed expression of SP-C (Fig. 15A-C). After being in culture two 
weeks with TGF-#1, prominin-1
+
 cells differentiated into fibroblast-like cells and 
confirmed expression of Col I (Fig. 15D-F). Finally, prominin-1
+
 cells cultured in 
presence of M-CSF showed phagocyting capacity, given by the presence of E. Coli 
bioparticles within the cytoplasm (Fig. 15G-I). 
 
 
 
Figure 15. Differentiation capacity of prominin-1+ cells expanded from GFP chimeric mice. MACS 
purified prominin-1+/GFP+ cells differentiated into SP-C+ alveolar type II cells when cultured in the 
presence of SAGM (A-C). In the presence of TGF-#1 and M-CSF, prominin-1+ cells differentiated into 
fibroblast- (D-F) and macrophage-like cells (G-I) respectively. SP-C (red, B), E. coli (red, E), Col I 
(red, H), 4’,6-diamidino-2-phenylindole (DAPI) (blue). Bars = 20 $m. 
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Single cell-derived colonies of prominin-1
+
 cells  
One of the criteria that define stem cells relies on their clonogenic ability, 
which is the capacity to give rise to single cell-derived colonies. To address these 
issues, prominin-1
+
 cells were plated as single cells. Cell cultured without feeder layer 
did not give rise to colonies and died after one week (data not shown). Therefore, we 
generated prominin-1
+
 cells from GFP expressing transgenic mice and co-cultured 
them on a GFP negative feeder layer. Up to 5 GFP
+
 cells were plated with 2 x 10
4
 
GFP
-
 cells. As illustrated, a single GFP
+
/prominin-1
+
 cell (Fig. 16A) gave rise to a 
GFP
+
 colony that expanded after 14 days (Fig. 16B). 
 
 
 
 
Figure 16. Prominin-1+ cells gave rise to single cell-derived colonies. GFP+/prominin-1+ cells cultured 
as single cell in presence of 2 x 104 GFP- feeder layer cells (A) show ability to give rise to colonies 
after two weeks (B). Bars = 30 $m. 
 
 
Next, we wanted to provide evidence that prominin-1
+
 progenitors from single 
cell-derived colonies could also differentiate into specialized cells. Thus, after 2-3 
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weeks GFP
+
 colonies were selected and transferred into new wells to induce in vitro 
differentiation into different lineages. 
As shown in Fig. 17A-C, cells cultured two weeks in presence of SAGM 
differentiated into SP-C
+
 alveolar type II cells. Single GFP
+
 differentiated cells were 
detectable among GFP
-
 cells. When plated in presence of M-CSF, cells differentiated 
into macrophage-like cells with phagocyting capacity (Fig. 17D-F). Finally, in 
presence of TGF-#1 cells differentiated into fibroblast-like which stained positive for 
Col I (Fig. 17G-I). 
 
 
 
 
Figure 17. GFP+/prominin-1+ progenitors expanded as single cells give rise to specialized cells. 
Prominin-1+ cells derived from single cell-derived colonies differentiated into type II pneumocytes (A-
C), macrophages (D-F) and fibroblasts (G-I). SP-C (red, B), E. coli (red, E), Col I (red, H), GFP 
(green), 4’,6-diamidino-2-phenylindole (DAPI) (blue). Bars = 20 $m. 
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Identification of two distinct prominin-1
+
 cell populations in the adult mouse lung 
We next wanted to address the presence of prominin-1
+
 cells within the 
healthy mouse lungs. Distal airways were isolated from adult mice and digested as 
described. FACS analysis revealed that the percentage of prominin-1
+
 cells 
correspond to 10.41 ± 0.98% (Fig. 18B); prominin-1
+
 cells were then stained for 
CD45 antibody. Analysis of samples showed that among the prominin-1
+
 subset, 6.82 
± 0.31% were co-expressing CD45 (Fig. 18D). Collectively, the percentage of 
prominin-1
+
/CD45
+
 cells in the adult mouse lungs corresponds to 0.71 ± 0.08%. In 
addition, staining of frozen sections confirmed the presence of two different cell 
phenotypes in the adult lung. In fact, rare, single round prominin-1
+
 cells were 
detected in the alveolar epithelium (Fig. 18F, asterisk), differently located from 
prominin-1
+
 cells sited along the bronchial epithelium (Fig. 18F, arrows). 
 
 
Figure 18. Characterization of prominin-1+ cells in mouse lungs. FACS analysis of adult mouse lungs 
(A-D). Prominin-1+ cells were gated (B) and stained for CD45 (D). The percentage of prominin-
1+/CD45+ cells within lungs corresponds to 0.71±0.08. (FL1 = unstained; Iso = Isotype control; SA = 
Streptavidin). Graphical visualization of the two prominin1+ subsets (E): a minority of prominin-1+ 
cells (6.87 ± 0.59%, violet) co-expressed CD45, whereas the majority of prominin-1+ cells (93.13 ± 
0.59%, grey) was CD45-. Immunohistochemistry on frozen sections confirmed the presence of two 
prominin-1+ distinct cell phenotypes located in the bronchial epithelium (white arrows) and alveolar 
epithelium (asterisk) (F). Lung frozen section stained with isotype control PE-conjugated (G). 
Prominin-1 (red), DAPI (blue). Bars = 20 $m. 
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Next, we performed further stains on frozen sections in order to characterize 
the two prominin-1 expressing populations. As confirmed in Figure 19, round 
prominin-1
+
 cells were detectable only in the alveolar epithelium, but they were all 
negative for type II specific marker SP-C (Fig. 19A-C) and for type I marker AQP5 
(data not shown). In addition they were all co-expressing CD45 (Fig. 19D-F).  
 
 
 
 
Figure 19. Characterization of pulmonary resident prominin-1+ cells. Stain of frozen sections from 
adult mouse lungs. Prominin-1+ cells located in the alveolar epithelium were negative for SP-C (A-C), 
but were all co-expressing CD45 (D-F). Prominin-1 was also expressed on the apical surface of 
bronchial epithelial (G) cells co-expressing "-tubulin IV (H-I). Prominin-1 (red), SP-C (green, B-C), 
CD45 (green, E-F), "-tubulin IV (green, H-I), 4’,6-diamidino-2-phenylindole (DAPI) (blue). 
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As already mentioned, the second subset of prominin-1
+
 cells was found in the 
bronchial epithelium and the expression was restricted on the apical surface (Fig. 
19G). As shown in Fig. 19H-I, these cells were all co-expressing "-tubulin IV, which 
stains for cilia and is specifically expressed on bronchial epithelial cells. These 
findings clearly show the presence of a hematopietic population of prominin-1
+
 cells 
and a second population of non-hematopoietic prominin-1
+
 epithelial cells. Analysis 
of lung suspensions from GFP chimeras revealed that only the CD45
+
/prominin-1
+
, 
but not the "-tubulin IV+/prominin-1+ fraction was of bone marrow origin (data not 
shown). 
Furthermore, analysis of cells taken from BALF excluded the presence of 
circulating prominin-1
+
 cells within pulmonary tissue. Accordingly, 
immunohistochemistry revealed that CD45
+
 cells present in the BALF, composed 
prevalently by macrophages, leukocytes and neutrophils, were not co-expressing 
prominin-1 (Fig. 20A-D). 
 
 
 
 
Figure 20. Prominin-1+cells are not present in mouse BALF. BALF was collected from adult mice 
lungs; cells were cyto-spun and stained. The totality of CD45+ cells was negative for prominin-1. CD45 
(green), prominin-1 (red), DAPI (blue). Bars = 30 $m. 
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Prominin-1
+
 cells sorted ex vivo expand in vitro and differentiate into alveolar type 
II epithelial cells 
In order to confirm that progenitor cells specifically expanded from the 
hematopoietic prominin-1
+
 population, we sorted ex vivo prominin-1
+
/GFP
+
 cells 
from chimeric mice and cultured them on a lung tissue-derived feeder layer. Up to 10 
GFP
+
 cells were cultured with 5 x 10
5
 feeder layer cells (Fig. 21A-C). Cells were kept 
in culture for up to 30 days. Already after 1 week single prominin-1
+
/GFP
+
 cells 
started to expand (Fig. 21, G) and gave rise to colonies (Fig. 21E, F, H, I). Transfer of 
prominin-1
+
/GFP
+
 cells into SAGM resulted in their differentiation into type II 
alveolar epithelial-like cells expressing SP-C (Fig. 21J-L). 
 
 
Figure 21. Prominin-1+cells sorted 
from chimeric lungs give rise to 
colonies and differentiate into type 
II cells.  Prominin-1+/GFP+ cells 
sorted from chimeric mice were 
FACS sorted, plated with 5 x 105 
feeder layer cells (A-C) and 
expanded (D-I). After expansion, 
GFP+ cells were incubated for 2 
weeks in the presence of SAGM 
and differentiated into SP-C 
positive cells (J-L). SP-C (red), 
GFP (green), 4’,6-diamidino-2-
phenylindole (DAPI) (blue). Bars 
= 20 $m. 
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Blood-derived prominin-1
+
 cells do not expand in vitro  
Our findings have shown that prominin-1
+
 cells originate from bone marrow. 
This indicates that prominin-1
+
 cells circulate through the peripheral blood and then 
home to the lung, replacing the local niche impaired after injury. Based on these 
observations, we wanted to investigate whether it would be possible to expand a 
population of prominin-1
+
 cells with similar feature from blood. 
First, we isolated and purified cells from blood of adult mice. Flow cytometry 
revealed that the amount of prominin-1
+
 cells in the blood corresponds 0.71±0.08% 
(Fig. 22A). Further analysis showed that nearly all prominin-1
+
 cells co-expressed 
CD45, CD34, CXCR4, c-kit (Fig. 22B). These data showed that prominin-1
+
 cells 
from blood share similar phenotype with human homologue AC133
+
 cells (241). 
 
 
 
 
Figure 22. Characterization of prominin-1+ from blood. Total amount of prominin-1+ cells in the blood 
is 0.71±0.08%. FACS analysis showed that prominin-1+ cells co-express with hematopoietic and stem 
cell markers (B). Prominin-1+ cells MACS sorted from blood did not attach and did not expand. 
Purified single prominin-1+/GFP+ cells were plated with 5 x 105 feeder layer cells. Single cells attached 
(E, F), but failed to expand and did not give rise to colonies (G, H). Bars = 20 $m. 
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Next, prominin-1
+
 cells were sorted from adult mice and plated in 6 well 
plates at a concentration of 5 x 10
5
 cells/well. Microscope analysis revealed that 
prominin-1
+
 cells did not attach to tissue culture plates (Fig. 22C) and did not expand 
(Fig. 22D). Therefore, we sorted prominin-1
+
 cells from the blood of GFP
+
 mice and 
plated as single cells with GFP negative lung-derived cultures. Prominin-1
+
/GFP
+
 
cells attached to the plates (Fig. 22E, F), but did not expand and did not give rise to 
colonies (Fig. 22G, H). 
 
 
Prominin-1
+
 cells differentiate in vivo into alveolar type II cells 
 
To address the differentiation capacity of prominin-1
+
 cells in vivo, sorted 
prominin-1
+
/GFP
+
 cells were intratracheally delivered into C57Bl/6 mice after BLM 
instillation. At day 1 after delivery, GFP
+
 cells were detected in the alveolar walls 
only and were negative for SP-C (Fig. 23A-C). In contrast, 7 days after delivery GFP
+
 
cells were still detected within the alveolar epithelium, but most of them also 
expressed alveolar type II specific marker SP-C (Fig. 23D-F). Importantly, GFP
+ 
cells 
did not engraft into the alveolar epithelium of unchallenged animals (data not shown). 
Taken together, these findings clearly demonstrate that prominin-1
+
 cells have 
the capacity to differentiate into type II pneumocytes in vivo. 
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Figure 23. Prominin-1+ cells differentiate into alveolar type II epithelial cells in vivo. Intratracheal 
injection of prominin-1+/GFP+ cells (E-J). GFP+ cells were detected only in alveolar walls after 1 day 
(E-G) and differentiated into SP-C positive type II alveolar epithelial cells after 7 days (H-J). SP-C 
(red), GFP (green), DAPI (blue). Bars = 30 $m. 
 
 
Prominin-1
+
 cells protect from bleomycin-induced pulmonary fibrosis 
At day 7 after intrapulmonary delivery of prominin-1
+
/GFP
+
 cells into BLM-
challenged mice (Fig. 23D-F), alterations in the alveolar epithelial architecture, 
typically affected after BLM treatment, were not evident. Given this observation, we 
set out to specifically address the reparative and protective capacity of prominin-1
+
 
cells in the BLM model. Figures 24A, D and G illustrate the architecture of the 
alveolar epithelium in unchallenged, PBS-injected mice (control). In BLM-challenged 
mice intratracheally injected with PBS the alveolar epithelium was massively 
damaged; in fact, histological analysis revealed considerable infiltration of 
inflammatory cells (Fig. 24B, E), extensive collagen deposition and progressive 
fibrosis (Fig. 24H). In contrast, intratracheal delivery of prominin-1
+
 cells to BLM-
challenged mice resulted in the preservation of an almost completely normal 
architecture of the alveolar epithelium for up to at least 21 days (Fig. 24C, F, I). 
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Importantly, injection of prominin-1 negative fraction sorted from cultures was not 
able to prevent the progression of pulmonary fibrosis (data not shown). 
 
 
 
 
Figure 24. Prominin-1+ cells administration prevents from BLM-induced lung fibrosis in mice. 
Hematoxylin and eosin (H&E)-stained histopathological sections from lungs of C57Bl/6 mice 21 days 
after saline exposure (A, D), BLM exposure (B, E) or BLM exposure and prominin-1+ cells (C, F). 
Masson’s Trichrome staining of lung sections from the same experimental groups (G, H, I). Original 
magnification: 25X (H&E) and 200X (H&E and Trichrome). Data are representative of at least five 
mice per condition. 
 
 
In addition, mice that received BLM reported significant loss of weight (Fig. 
25A, black squares); on the other hand, administration of prominin-1
+
 cells into 
BLM-challenged mice also protected from progressive loss of body weight (Fig. 25A, 
grey triangles). Importantly, whereas BALF samples taken at days 3 and 7 from 
BLM-treated control mice injected with PBS only had increased numbers of total 
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cells, samples taken from BLM-challenged mice injected with prominin-1
+
 cells did 
not (Fig. 25B). Injection of prominin-1
+
 cells resulted in noteworthy reduction of 
neutrophils and macrophage recruitment to the injured lungs (Table 2).  
Real Time PCR analysis of day 7 lung samples from prominin-1
+
 cells-treated 
mice showed no up-regulation of IL-4, IL-6, IL-13 and TNF-!, nor of the chemokines 
CCL2, MIP-1!, and MCP-5 mediating inflammatory cell recruitment (41, 242) (Fig. 
25C). Pro-fibrotic genes such as TGF-"1 and genes of cytokines mediating fibrocytes 
recruitment, such as SDF-1! or CCL21 (22, 24) were also not up-regulated in 
prominin-1
+
 cells-treated animals at day 21 (Fig. 25D). 
 
 
 
 
Figure 25. Effect of prominin-1+ cells injection on BLM-induced lung fibrosis in mice. Body weight 
measurement from animals injected with saline (white), BLM (black) or BLM and prominin-1+ cells 
(grey) (A). The number of total cells in BALF of the three groups at day 3 and day 7 (B). Quantitative 
Real Time PCR on lungs collected at the peak of inflammation (day 7) (C) and at the fibrotic stage 
(day 21) (D) after BLM instillation. The panels summarize the quantitative results after normalization 
to the GAPDH signal. Bars represent mean ± SD (n=3).  
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Parameter 
PBS 
day 3 
(n=3) 
BLM 
day 3 
(n=3) 
BLM + 
prominin-1
+
 
day 3 (n=3) 
PBS 
day 7 
(n=3) 
BLM 
day 7 
(n=3) 
BLM + 
prominin-1
+
 
day 7 (n=3) 
Total (x10
6
) 0.251±0.036 0.630±0.144 0.261±0.067 0.270±0.040 1.145±0.163 0.343±0.045 
Neutrophils 0.002±0.002 0.278±0.083 0.006±0.003 0.003±0.002 0.450±0.147 0.011±0.008 
Lymphocytes 0.004±0.003 0.076±0.028 0.007±0.002 0.005±0.001 0.177±0.036 0.027±0.007 
Macrophages 0.245±0.034 0.276±0.035 0.248±0.050 0.262±0.039 0.518±0.009 0.305±0.042 
 
Table 2. Analysis of bronchoalveolar lavage (BAL) cell differentials. Data represent mean ± SD. 
 
 
Accordingly, FACS analysis on blood samples revealed that the number of 
circulating fibrocytes (CD45
+
/Col I
+
/CXCR4
+
) and did not increase in mice that had 
received prominin-1
+
 cells (Fig. 26). 
 
 
 
 
Figure 26. Injection of prominin-1+ cells prevents from recruitment of circulating fibrocytes in mouse 
blood. FACS analysis on blood samples taken at day 14 from BLM or prominin-1+ cells-treated mice. 
The percentage of fibrocytes (CD45+/Col I+/CXCR4+) did not increase in blood of mice that received 
prominin-1+ cells compared with blood taken from mice treated with BLM alone. Bars represent mean 
± SD (n=3). 
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Taken together, these results indicate that intratracheal administration of 
prominin-1
+
 cells specifically prevents the recruitment of inflammatory cells, 
abnormal extracellular matrix remodeling and pulmonary fibrosis in BLM-challenged 
mice. 
 
 
Prominin-1
+
 cells suppress alveolar macrophage proliferation  
To specifically address the mechanism whereby prominin-1
+
 cells mediate 
suppression of BLM-induced fibrosis, we focused on the early stages of disease 
development in this injury model. We compared the expression of various pro- and 
anti-inflammatory genes in day 1 lungs of control PBS-treated mice, and BLM-
challenged mice treated or not with prominin-1
+
 cells (Fig. 27). As illustrated, we did 
not observe up-regulation of Th2 cell specific cytokines such as IL-4 and IL-13 in 
mice that received prominin-1
+
 cells. 
 
 
 
 
Figure 27. Injection of prominin-1+ 
cells prevents from up-regulation of 
pro-inflammatory genes. Real Time 
PCR performed on lungs of mice 
challenged with buffer saline (PBS), 
bleomycin (BLM) alone or BLM + 
prominin-1+ cells. Lungs were 
harvested at day 1 after treatment. The 
panel summarizes the quantitative 
results after normalization to the 
GAPDH signal. Bars represent mean ± 
SD (n=3). 
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Consequently, we hypothesized that T cells might be the targets of prominin-
1
+
 cells, and therefore involved in the pathogenesis of IPF, despite the fact that recent 
studies have been shown to be controversial regarding their role (36, 38). Advances in 
the study of immune reactions have shown that an imbalance between type 1 helper T 
cells (Th1) and type 2 helper T cells (Th2) plays a pivotal role in the inflammatory 
response in various diseases (243). Studies have revealed a predominance of the Th2-
type cytokine pattern in inflammatory response of IPF. In vivo studies using a 
bleomycin (BLM)-induced pulmonary fibrosis model have also supported this 
concept by demonstrating that IL-4 mRNA expression is up-regulated in lung fibrosis 
lesions. The Th2-like pattern of immune response predominated in the infiltrating 
interstitial inflammatory cells and hyperplastic type II epithelial cells of patients with 
IPF (244, 245). We therefore isolated CD4
+
 T cells from BLM-treated animals and 
co-cultured (5 x 10
4
 cells) with irradiated prominin-1
+
 cells at different cell ratio. As 
shown in Fig. 28, prominin-1
+
 cells suppressed T-cells proliferation in a dose-
dependent manner. 
 
 
Figure 28. Proliferation of T cells is 
suppressed in vitro in the presence of 
prominin-1+ cells in a dose-dependent 
fashion. 5 x 104 CD4+ naïve T cells isolated 
from BLM-treated animals and previously 
stimulated with plate-bounds anti-
CD3/anti-CD28 antibody were co-cultured 
with decreasing amount of irradiated 
prominin-1+ cells. Cell proliferation was 
measured by [3H]Thymidine incorporation 
(cpm = counts per minute). Bars represent 
mean ± SD (n=3).
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In order to prove the involvement of T cells in the pathogenesis of BLM-
induced fibrosis, we next injected BLM into the lungs of RAG2
-/-
 mice. RAG2
-/-
 
animals show total inability to initiate V(D)J rearrangement, leading to a severe 
combined immune deficient (SCID) phenotype; these mice lack the protein necessary 
to recombine the DNA at the loci of the T-cell receptor and the immunoglobulin 
genes, resulting in absent T cells and B cells (246). 
As illustrated in Fig. 29, RAG2
-/-
 mice injected with PBS showed normal 
pulmonary architecture, absence of infiltration of inflammatory cells (Fig. 29A) and 
collagen deposition (Fig. 29D). On the other hand, RAG2
-/-
 mice that received BLM 
were not protected from development of pulmonary fibrosis (Fig. 29B, E) and showed 
a histological pattern comparable to RAG2
+/+
 mice (Fig. 29C, F). Furthermore, an 
adoptive transfer of CD4
+
 T cells isolated from BLM-treated mice into lungs of non-
treated animals did not result in initiation of pulmonary fibrosis (data not shown). 
 
 
 
 
Figure 29. RAG2-/- mice are not protected from BLM-induced pulmonary fibrosis. Lungs of RAG2-/- 
and RAG2+/+ animals were harvested at day 21 following BLM injection, sectioned, and stained with 
hematoxylin and eosin (H&E) (A-C) or CAB (D-F). Photomicrographs are representative of at least 
three mice per condition. Original magnification: 200X. 
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Taken together, these findings clearly explain that T cells are not essential 
players in the context of BLM-induced lung injury, and therefore they do not 
represent the main target of prominin-1
+
 cells. 
However, lungs of prominin-1
+
 cells-treated mice also did not display up-
regulation of KC/CXCL1 and CCL2 (Fig. 27), chemokines mainly produced by 
macrophages, which are considered as key players for the onset of pulmonary fibrosis 
in the BLM-induced injury model (41). Additionally, BLM-challenged mice injected 
with prominin-1
+
 cells showed significant up-regulation of inducible nitric oxide 
synthase (iNOS) (Fig. 27). Current evidence suggest a regulatory effect of nitric oxide 
(NO) in many cell types (215, 217, 219, 220) and a protective role in various lung 
disease models (221, 222, 224). To clarify whether prominin-1
+
 cells or alveolar 
macrophages (AM) were major NO producers, and to specifically assess effects of 
prominin-1
+
 cells on the proliferation of AM, we performed co-culture experiments. 
As illustrated in Fig. 30A, the proliferation of AM was dramatically reduced when 
cultured in the presence of prominin-1
+
 cells. Prominin-1
+
 cells-induced suppression 
of AM proliferation required cell-to-cell contact between AM and prominin-1
+
 cells 
(Fig. 30C). Compared with individual cultures of AM or prominin-1
+
 cells, NO 
release was markedly increased in the supernatant of AM and prominin-1
+
 cells co-
cultures (Fig. 30B). To evaluate the role NO in growth arrest, we first assessed 
proliferation responses in the presence of the non-specific NO synthase inhibitor L-
NAME. As shown in Fig. 30D, addition of L-NAME neutralized the effect of 
prominin-1
+
 cells and restored AM proliferation capacity. We next expanded 
prominin-1
+
 cells from iNOS deficient mice and co-cultured them with AM. iNOS
-/- 
prominin-1
+
 cells did not suppress the proliferation of AM in vitro (Fig, 30A). NO 
levels increased only in co-cultures of AM with iNOS
+/+
, but not iNOS
-/-
 prominin-1
+
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cells (Fig. 30B), confirming that NO was produced specifically by prominin-1
+
 cells. 
It is noteworthy that NO production did not differ between irradiated and non-
irradiated prominin-1
+
 cells and occurred only when cells were stimulated with LPS 
and IFN-! (Fig. 30E). Taken together, our findings suggest that prominin-1
+
 cells 
directly inhibit the proliferation of AM, which are critical for disease development in 
the BLM-induced lung injury model (41). In addition, our in vitro data argue for a 
critical role of NO in regulation of AM proliferation. 
 
 
 
 
Figure 30. Proliferation of alveolar macrophages (AM) is suppressed in the presence of iNOS+/+ 
prominin-1+ cells but not in the presence of iNOS-/- prominin-1+ cells (A). Nitrite levels reflecting NO 
production in culture supernatants increase when AM are cultured in the presence of iNOS+/+ prominin-
1+ cells but not in the presence of iNOS-/- prominin-1+ cells (B). The suppressive effects of prominin-1+ 
cells require close contact to AM (C). Inclusion of the NOS inhibitor L-NAME, but not its inactive 
enantiomer D-NAME, restores proliferation of AM in the presence of prominin-1+ cells (D) (cpm = 
counts per minute). Prominin-1+ cells produced NO only when stimulated with LPS and IFN-!. No 
difference was found between irradiated and non-irradiated prominin-1+ cells (E) (irr. = irradiated; n.s. 
= not stimulated). [3H]-Thymidine incorporation was measured as the readout for proliferation. Bars 
represent mean ± SD (n=3). *p < 0.01. 
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Nitric oxide mediates the protective effects of prominin-1
+
 cells  
To address the role of iNOS and NO in the prominin-1
+
 cells-mediated 
suppression of BLM-induced lung injury in vivo, we injected BLM-challenged mice 
with either iNOS
+/+
 or iNOS
-/- 
prominin-1
+
 cells. BALF was collected at day 7. The 
number of total cells in BALF from mice injected with iNOS
+/+
 prominin-1
+
 cells was 
comparable to the BALF of mice challenged with PBS only (Fig. 31A). However, 
BALF from BLM-challenged mice injected with iNOS
-/-
 prominin-1
+
 cells contained 
a markedly increased number of total cells. H&E- and Masson’s Trichrome-staining 
of lung sections from iNOS
-/- 
prominin-1
+
 cells-treated animals revealed the presence 
of inflammatory foci and collagen deposition (Fig. 31 E, I, M), comparable to that in 
lungs from BLM-challenged mice (Fig. 31 C, G, K). 
 
 
 
 
Figure 31. Intratracheal injection of iNOS-/- prominin-1+ cells does not protect from BLM-induced 
pulmonary fibrosis. The total cell number in BALF is comparable in mice injected with BLM alone 
and BLM + iNOS-/- prominin-1+ cells. The total number of cells is similar in BALF from mice exposed 
to saline buffer or BLM + iNOS+/+ prominin-1+ cells (A). *p < 0.01. Bars represent mean ± SD (n=3). 
Lungs were harvested, sectioned, and stained with hematoxylin and eosin (H&E) (B-I) or Masson’s 
trichrome (J-M). Photomicrographs are representative of at least five mice per condition. Original 
magnification: 25X (H&E) and 200X (H&E and Trichrome). 
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In conclusion, bone marrow-derived prominin-1
+
 cells expanded from mouse 
lungs possess regenerative capacity and striking anti-inflammatory properties, and 
protect BLM-treated mice from pulmonary fibrosis in a NO-dependent manner. 
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Discussion 
 
My thesis describes the discovery of a novel population of prominin-
1/CD133
+
 bone marrow-derived lung progenitors from adult mouse lungs with 
multilineage differentiation capacity in vitro, and anti-inflammatory and regenerative 
properties in vivo. 
In support of the hypothesis that lung injury exceeding a certain threshold is 
necessary to activate stem/progenitor cell expansion, we found that dissection of 
pulmonary tissue resulted in the expansion of a small, round, undifferentiated 
population of prominin-1
+
 cells growing on feeder layer cells with mesenchymal 
phenotype. Our data illustrated that density was critical in maintaining in vitro the 
round phenotype of prominin-1
+
 cells.  
Recent studies have shown the presence of stem cell populations within lungs 
(103, 247). Our sorted prominin-1
+
/CD45
+
 cells were negative for SP-C and CC10. 
Accordingly, they represent a distinct subset from bronchioalveolar stem cells 
(BASCs) (103), which in contrast co-express both SP-C and CC10. BASCs were 
identified at the bronchioalveolar duct junction within the terminal bronchioles, 
whereas prominin-1
+
/CD45
+
 cells were located in the alveolar epithelium. 
Furthermore, our prominin-1
+
 cells were of hematopoietic origin and clearly 
expressed a phenotype different from the BASCs and lung Side Population (SP) 
mesenchymal stem cells described by Summer and colleagues (247). Similarly to 
BASCs, prominin-1
+
 progenitor cells exhibited multipotent properties. In fact, 
depending on culture conditions, prominin-1
+
 cells showed multineage capacity and 
differentiated in vitro into three different cell types, acquired a different phenotype 
and changed their gene and protein profile. Since single cell-derived clones showed 
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capacity to differentiate into epithelial (alveolar type II cells), mesenchymal 
(fibroblasts) and hematopietic (macrophages) phenotypes, prominin-1
+
 progenitors 
can be considered as multipotent progenitor cells. These data clearly highlight the 
plasticity of prominin-1
+
 progenitors in vitro. Given their capacity to differentiate into 
inflammatory cell and fibroblast phenotype, it remains to be established whether 
prominin-1
+
 cells could play a role in the context of inflammatory pulmonary disease. 
Since prominin-1
+
 cells acquired the expression of collagen type I after fibroblast 
differentiation, they might also contribute to collagen deposition and progression of 
pulmonary fibrosis. Data from our laboratory illustrated that cardiac prominin-1
+
 
progenitors differentiated in vivo into macrophages and fibroblasts when injected 
during inflammatory stage within adult heart tissue in a mouse model of autoimmune 
myocarditis. Collectively, these data emphasize the plasticity of prominin-1
+
 cells in 
different organs.  
However, prominin-1
+
 cells did not give rise to progenies when plated as 
single cells without feeder layer. The ultimate test for stem cell activity is a single-cell 
clonogenic transplantation assay, as has been done in the hematopoietic system (248, 
249) However, such assays are particularly challenging when applied to stem cells of 
epithelial tissues. Epithelial cells are closely associated with endothelial cells, stromal 
fibroblasts, inflammatory cells, and accompanying extracellular matrix and cell-to-
cell interactions. Some or all of these components may be required to allow survival, 
engraftment, and proper differentiation of putative stem and progenitor cells. 
Although there is an established protocol in order to allow stem cells to repopulate the 
mammary tissue without injection of additional exogenous supporting cells (104, 250-
252), a comparable system remains to be created for other epithelial tissues, including 
the lung. 
 69 
We have demonstrated that the healthy mouse lungs displayed two distinct 
prominin-1
+
 phenotypes. Prominin-1/CD133 expression has already been described 
for different adult epithelial cells (253). We identified for the first time the presence 
of a population of prominin-1
+
/CD45
+
 cells within the adult mouse lung. On the other 
hand, the majority of prominin-1
+
 cells belonged to the bronchial epithelial ciliated 
population. Accordingly, our findings are consistent with recent work of Shmelkov 
and collaborators (182) demonstrating the presence of prominin-1
+
 cells along the 
bronchial epithelium. Moreover, our data have shown that the cuboidal prominin-
1
+
/"-tubulin IV+ cells were not of bone marrow origin, whereas the prominin-
1
+
/CD45
+
 cells were also GFP positive and clearly bone marrow-derived. Notably, 
prominin-1
+
/GFP
+
 cells sorted ex vivo from chimeric lungs expanded only in the 
presence of a feeder layer. This observation suggests that lung-derived cells might 
specifically trigger the expansion of bone marrow-derived resident prominin-1
+
 
pulmonary progenitors. On the other hand, in the same conditions it was not possible 
to expand in vitro prominin-1
+
 cells isolated from mouse blood. These records clearly 
exclude that prominin-1
+
 cells expanded from lungs could represent a residual of 
blood cells. 
Immunohistochemistry showed that prominin-1
+
/CD45
+
 cells were associated 
with the alveolar epithelium in vivo. Prominin-1
+
 cells expanded from adult tissue 
differentiated in vitro into type II epithelial cells. Based on their expression of type II 
alveolar specific gene SP-C, but not bronchial epithelial CC10, prominin-1
+
 cells may 
represent a specific early committed alveolar progenitor population. In support of this 
view, intratracheal injection of prominin-1
+
 cells in BLM-challenged mice resulted in 
straight differentiation towards a type II epithelial phenotype. These data underscore 
the striking regenerative potential of prominin-1
+
 cells in vivo. It is important to 
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underline that prominin-1
+
 cells engrafted into the alveolar walls of the lungs of 
BLM-challenged animals only. These findings support the view that tissue injury is 
necessary to create a specific microenvironment that promotes engraftment and 
subsequent differentiation of prominin-1
+
 cells. Our data are consistent with other 
studies that have demonstrated the occurrence of tissue-specific differentiation of 
engrafted bone marrow cells only in challenged animals (155, 160, 254, 255). 
Besides, it is of particular interest the finding that prominin-1
+
/CD45
+
 cells 
reside within the pulmonary alveolar epithelium. A recent work has shown that the 
expression of prominin-1 in human lung tissue was associated with rapid progression 
of IPF (256), and prominin-1 expression was predominantly expressed in the areas of 
the alveolar lesions. In addition, in a model of lung cancer, mice develop atypical 
adenomatous hyperplasias (hyperproliferations of alveolar type II cells) that progress 
to adenomas and then overt adenocarcinomas (257). Together with the observation 
that the adenocarcinomas were positive for the alveolar type II cell-specific marker 
SP-C, these data implicate that type II cells are the target cells in rodent and human 
lung adenocarcinomas. Recent findings have already shown that lung tumors can arise 
from expansion of stem cells (103); furthermore a novel population of prominin-1
+
 
expressing tumorigenic stem cells has been identified in human in small cell and non-
small cell lung cancer (189). Given the location of prominin-1
+
/CD45
+
 as regional 
pulmonary stem cells and as precursors in vivo for type II cells, they might possibly 
represent a target cell population in tumorigenesis or fibrosis. In addition, unpublished 
observations have shown that the percentage of prominin-1
+
/CD45
+
 cells increase 
after BLM treatment; moreover, immunohistochemistry revealed that a significant 
increase of prominin-1
+
 cells within the alveolar epithelium (data not shown). It 
remains to be established whether the increase of prominin-1
+
/CD45
+
 cells is due to 
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migration of bone marrow-derived cells from the circulation or due to activation of 
resident prominin-1
+
/CD45
+
 progenitor cells. If so, it might be possible to target and 
activate these cells and redirect towards epithelial differentiation in order to restore 
the damaged tissue. Similarly, administration of both keratinocyte growth factor and 
hepatocyte growth factor to animals with lung injury has been shown to stimulate 
alveolar epithelial cell proliferation (258-260). Given these remarks, prominin-1 
expressing progenitors might symbolize a double-edged sword: on one hand, 
prominin-1
+
 cells could represent a cellular source for tissue regeneration; on the 
other hand, they might contribute to fibrosis or even lung cancer. Nevertheless, 
contribution, involvement and activation of pulmonary prominin-1
+
 progenitors after 
alveolar injury will need to be carefully investigated. A major task will be required to 
figure out under which conditions resident cells will exert a protective effect in vivo. 
Accumulating evidence supports a beneficial role of administered stem or 
precursor cells in several injury models (200, 261-265). Here we have demonstrated 
that intratracheal injection of prominin-1
+
 cells in the BLM-injury model resulted in 
complete protection from pulmonary fibrosis. It is important to underline that 
administration of prominin-1 negative fraction did not decrease the pro-inflammatory 
and pro-fibrotic response to BLM (data not shown). This finding clearly states the 
specific immunomodulatory effect of prominin-1
+
 cells. Other studies have shown 
that injection of bone marrow-derived stem cells can ameliorate BLM-induced lung 
fibrosis (25, 155). In line with these studies, we found that beneficial effects occur 
only when prominin-1
+
 cells are injected during the early phases after BLM 
instillation. Intrapulmonary delivery of mesenchymal stem cells has been shown to 
attenuate the effects of pulmonary injury in different animal models when 
administered at early stages (266, 267), indicating that hematopoietic and 
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mesenchymal stem cells share similar immunological properties. As illustrated, only a 
small amount of GFP
+
/prominin-1
+
 cells engrafted into the alveolar walls and 
differentiated into type II epithelial cells. Our data are in line with other studies 
showing relatively minimal contribution of donor cells to the alveolar epithelium. 
Given these findings, we believe that the primary effect of prominin-1
+
 progenitors 
results in an immunomodulatory action, whereas the engraftment might represent only 
a secondary consequence. Besides, it remains to be established whether bone marrow-
derived stem cells might exert a similar protective potential in reverting BLM-induced 
effects at the late stages of fibrosis. In the presence of pro-fibrotic cytokines and 
massive damage to the whole alveolar epithelium, a higher number of cells might be 
required to exert an adequate response. 
Our study also demonstrates that prominin-1
+
 cells exerted an anti-
inflammatory effect in vivo and suppressed alveolar macrophages proliferation in 
vitro. Baran and colleagues (41) have shown that the presence of macrophages is 
crucial for development of BLM-induced fibrosis. The fundamental role of alveolar 
macrophages in the context of lung injury has been similarly noted in other studies 
(268-270). We found that injection of prominin-1
+
 cells suppressed the production of 
cytokines secreted by macrophages, such as KC/CXCL1, which might explain the 
consequential lack of neutrophils recruitment to the lungs of prominin-1
+
 cells-treated 
BLM-challenged mice. In addition, no up-regulation of SDF-1! was found in lungs of 
the prominin-1
+
 cells-treated mice. Lack of SDF-1! up-regulation, as well as CCL21, 
cytokines mainly produced also by macrophages, might be responsible for the 
impaired recruitment of circulating fibrocytes (24) and bone marrow-derived 
fibroblasts to injured lung (22). Accordingly, flow cytometry analysis of blood 
samples taken from animals that received prominin-1
+
 cells confirmed that no 
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recruitment of fibrocytes was found, suggesting that the anti-inflammatory effect 
resulted also in the abolishment of a more systemic reaction. 
The suppressive effect of prominin-1
+
 cells-treatment on AM proliferation was 
critically mediated by NO production. In vitro, AM growth suppression was restored 
in presence of NO inhibitor, L-NAME. In accordance with this finding, prominin-1
+
 
cells expanded from iNOS
-/-
 mice could not suppress alveolar macrophages 
proliferation in vitro and failed to protect from BLM-induced injury in vivo. 
Interestingly, our data show that prominin-1
+
 cells do not secrete NO without LPS 
and IFN-# stimulation. This observation suggests that a specific environment (e.g. 
inflammation) is necessary to render prominin-1
+
 cells capable to exert NO-mediated 
immunomodulatory effects. Of note, the administration of NO-producing cells such as 
bone marrow-derived macrophages and bone marrow-derived dendritic cells did not 
exert any protective effect, therefore emphasizing the specific immunomodulatory 
role of prominin-1
+
 cells. Unlike prominin-1
+
 cells, other NO-producing cells might 
secrete pro-inflammatory factors that in turn compensate the beneficial effect of NO. 
Likewise, a recent study from our lab has shown that bone marrow-derived prominin-
1/CD133
+
 cardiac progenitors protect from autoimmune myocarditis in mice through 
a NO-mediated mechanism (200). Our data are consistent with the reported benefits 
of NO inhalation in other lung injury models (223, 224), confirming that low 
concentration of NO exert a protective effect, despite the evidence that iNOS
-/-
 mice 
are protected from BLM-induced fibrosis (271). Recent findings have shown that 
exogenous NO can attenuate the EMT that affects alveolar type II cells (238). In fact, 
EMT has been shown to occur both in vitro (231, 232) and in vivo (231-233) and 
involve significantly type II pneumocytes that, consequently, give rise to 
myofibroblast-like cells. Thus, we cannot exclude that prominin-1
+
 cells targeted not 
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only macrophages, but also type II pneumocytes, preventing in this way also the 
transition to myofibroblasts. Collectively, these findings strongly support the view 
that NO-dependent mechanisms play a critical role in prominin-1
+
 cells protection 
from BLM-induced pulmonary fibrosis. 
Prominin-1
+
 progenitors represent a population of bone marrow-derived cells. 
Prominin-1
+
 cells are also found in blood and bone marrow of healthy animals, but do 
not share analogous regenerative and immunomodulatory properties with prominin-1
+
 
cells (data not shown). We believe that either the specific microenvironment created 
by disintegration of whole pulmonary tissue, or inflammatory processes are critical 
for the activation and expansion of immunomodulatory and regenerative prominin-1
+
 
cells. Appropriate adaptation and optimization of culture conditions for blood- or 
bone marrow-derived cells might enable isolation and expansion of vast numbers of 
immunomodulatory/regenerative cells from the peripheral circulation. 
Autologous stem cell transplantation could be used to overcome the problem 
of immune rejection in regenerative medicine. Adult stem cells could be transplanted 
into a new niche where they would be able to repopulate the cells of defective tissue. 
Stem cells purified from bone marrow, blood, or umbilical cord could be also stored 
before a major operation or when it is predicted that a patient is at risk of acute lung 
injury. As an agent of combination therapy, stored stem cells would be injected back 
into patients with acute lung injury to enhance lung repair and to generate functional 
alveolar structures or enhanced surfactant. There is great excitement and potential 
with these therapies, but at present the field is littered with controversies and 
questions (272). Although we are some way off from clinical trials with bone marrow 
stem cells in parenchymal lung disease until some issues are clarified, such is the 
promise of this therapy that it has already been used in human cardiac trials. 
 75 
Collectively, there is a considerable safety record with clinical use of stem cells, 
consisting in transplantation of bone marrow-derived cells. Initial exploratory trials, 
phase 1 or otherwise, can be safely designed and implemented with appropriately 
measurable outcome assessments. In fact, there are many patients with end-stage lung 
diseases who are already offering to participate in clinical trials and investigations. 
Although patients with end-stage lung diseases may not be the optimal population to 
study, initial investigations might provide important data about safety and will 
generate future hypotheses for study. Unfortunately, pulmonary and critical care 
medicine has traditionally lagged behind other fields, for example, cardiology and 
hematology, in translational studies of potential new therapies, including the use of 
reparative cells. In fact, clinical trials in cardiology (273) have demonstrated the 
feasibility and safety of administering progenitor cells derived from autologous bone 
marrow to the myocardium of patients with ischemic heart disease. The few 
controlled trials that have been completed so far show a tendency to improved heart 
function in transplanted patients after myocardial infarction, and in those with chronic 
ischemic heart failure (273). 
Despite many safety records for patients who underwent bone marrow 
transplantation, there is not enough information about long-term effects of stem cell 
engraftment within adult tissues. Cogent examples are the publications demonstrating 
development of gastric cancer from transplanted stem cells in a mouse model of 
chronic H. pylori infection and the potential role of adult stem cells in development of 
cancer (274, 275). 
Advances in stem cell biology and technology will eventually turn cell 
transplantation into a useful treatment for patients with a variety of diseases and 
injuries, including genetic diseases involving lung and acute lung injury. However, 
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much more research on how to purify stem cells and how to direct the differentiation 
of stem cells and to stimulate regeneration and functional recovery is needed. 
Although stem cell therapy in the lung has great promise, further basic science 
research is needed before this treatment can be confidently moved to the bedside. 
 
 
Conclusion 
We successfully expanded a population of bone marrow-derived progenitor 
cells with multilineage differentiation capacity from adult mouse lungs. The cells 
were characterized by prominin-1
+
 expression and showed in vitro and in vivo 
immunosuppressive and regenerative capacities. Our study therefore represents an 
important step toward the development of novel cell-based therapies for pulmonary 
fibrosis, the common final pathway of several interstitial lung diseases. Future 
projects must focus on the identification of related prominin-1
 
expressing progenitors 
in human lung biopsy samples (Fig. 32). 
 
 
 
 
 
Figure 32. Potential therapeutic 
applications of prominin-1+ cells. 
Prominin-1+ progenitors might be isolated 
from human biopsies (1), expanded in vitro 
(2) and injected back into donor patients 
affected by pulmonary disorders (3); 
alternatively, prominin-1+ cells might 
differentiate into alveolar type II cells (4) 
and injected to replace damaged cells (5). 
In addition, following pharmacological 
activation (6), resident prominin-1+ 
progenitors might be redirected towards 
epithelial differentiation in order to restore 
the injured tissue. 
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